PCT

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : **C07K 14/72, 14/70**	**A2**	(11) International Publication Number: **WO 97/35881** (43) International Publication Date: 2 October 1997 (02.10.97)

(71)(72) Applicants and Inventors: NG, Gordon, Y., K. [CA/CA];
38 Elm Street #3300, Toronto, Ontario M5G 2K5 (CA).
SEEMAN, Philip [CA/CA]; 32 Parkwood Avenue, Toronto,
Ontario M4V 2X1 (CA). GEORGE, Susan, R. [CA/CA];
54 Thornbank Road, Thornhill, Ontario K4J 2A4 (CA).
O'DOWD, Brian, F. [CA/CA]; 229 Catalina Drive, Scar-
borough, Ontario M1A 1B8 (CA).

(74) Agent: RAE, Patricia, A.; Sim & McBurney, 6th floor, 330
University Avenue, Toronto, Ontario M5G 1R7 (CA).

(54) Title: RECEPTOR AND TRANSPORTER ANTAGONISTS

(57) Abstract

Specific antagonists for prokaryotic or eukaryotic integral membrane proteins are provided. The antagonists are peptides having the amino acid sequence of a transmembrane domain of the integral membrane proteins or of a portion of analogue thereof. Methods are provided for preventing or treating disorders characterised by disordered function of an integral membrane protein by administration of a specific peptide antagonist of the integral membrane protein.

1

RECEPTOR AND TRANSPORTER ANTAGONISTS

Related Applications:

This application claims priority from U.S.
5   Provisional Patent Application No. 60/014,306 filed on
March 27, 1996, U.S. Patent Application No. 08/670,119,
filed June 25, 1996 and U.S. Provisional Patent
Application No. 60/024,240 filed August 20, 1996.

10   Field of the Invention

This invention relates to the field of integral
membrane proteins which act as receptors or signal
transducers. More specifically, it relates to the
identification and preparation of specific antagonists of
15   the function of such proteins.

Background of the Invention

Various journal articles referred to herein are
identified by authors and date in parentheses and are
20   listed, with full citations, at the end of the
specification.

Receptors are the primary targets and mediators of
hormone and drug actions. The cell surface receptors,
such as the G protein-coupled receptors (GPCRs), ion
25   channel receptors, immunoglobulin receptors and tyrosine
kinase receptors, belong to gene superfamilies based on
sequence and structural similarities. Receptors belonging
to these superfamilies are all integral membrane proteins
predicted to exhibit extracellular, hydrophobic membrane-
30   spanning and intracellular domains. Whereas tyrosine
kinase receptors and most immunoglobulin receptors
exhibit a single membrane spanning domain, G protein-
coupled receptors are defined by seven putative
hydrophobic membrane spanning segments which have become

2

the hallmark of this gene superfamily. The biogenic
amine transporter proteins are also membrane-spanning
proteins, with twelve transmembrane segments, that
mediate the reuptake of released neurotransmitter. The
5   ion channel receptors generally have separate subunits
that associate together to form a functional receptor.

The amino acid sequence of a receptor protein, which
is unique to each receptor, confers specific structure-
related functions to the receptor, while conforming to
10   the general structural determinants of the particular
class of protein to which it belongs. The amino acid
sequence of an integral membrane protein, such as a
receptor or transporter protein, determines the
hydrophobic and hydrophilic portions, and has been used
15   in the development of algorithms for the prediction of
membrane protein secondary structure (Engelman et al.,
1986, Kyte and Doolittle, 1982). Peptide probes derived
from regions of various proteins have been used for
mapping structural determinants of proteins. This has
20   been best characterized for the single transmembrane
spanning sialoglycoprotein, glycophorin A, isolated from
human erythrocyte membranes (Furthmayr and Marchesi,
1976). In these studies, a small hydrophobic peptide
derived from glycophorin A was able to prevent the
25   association of 2 subunits *in vitro*, which suggested that
native glycophorin A in membranes is composed of subunits
associated with each other by hydrophobic portions of the
polypeptide chains. Subsequent studies demonstrated that
a specific molecular motif (LIxxGVxxGVxxT) participates
30   in the formation of glycophorin A dimers (Bormann et al.,
1989, Lemmon et al., 1992).

For the G protein coupled receptors, Okamoto et al.
(1991) used a synthetic peptide corresponding to the end
of the third cytoplasmic loop of the G protein-coupled

β2-adrenergic receptor to demonstrate that this amino acid sequence was critical for this receptor's ability to activate G proteins. In addition, it has been shown that coexpression of the third intracellular domain of the G

5   protein-coupled α1B-adrenergic receptor, along with the receptor specifically inhibited receptor-mediated inositol phosphate production (Luttrell et al., 1993), and that expression of the intracellular third loop of the dopamine D1 receptor specifically inhibited receptor-

10   mediated cAMP production (Hawes et al., 1994).

For the tyrosine kinase receptors, the investigation of an activating mutation of the *neu* oncogene in the rat revealed that co-expression of short transmembrane molecules encoded by DNA constructs retarded the growth

15   of *neu* transformed cells (Lofts et al., 1993).

GPCRs have been shown to exist as dimers and monomers in the presence of denaturants and reducing agents (Ng et al., 1993, 1994a, 1994b), suggesting that dimerisation does not occur via covalent disulphide

20   bonds. It has been hypothesised that the seven transmembrane(TM) spanning domains of GPCRs are sequentially arranged in an anti-clockwise circular manner forming a TM receptor core (Baldwin, 1993). The proper folding of GPCR monomers is suggested to involve

25   intramolecular interactions between TMI and TMVII (Kobilka et al., 1988, Suryanarayana et al., 1992). Coexpression studies with chimeric GPCRs have suggested that receptor interactions may involve TMVI and VII (Maggio et al., 1993, Liu et al., 1995), and mutagenesis

30   studies have demonstrated that antagonist interaction with the receptors may involve these TM regions.

The importance of membrane-spanning proteins such as receptors and transporters in signal transmission across the cell membrane makes these proteins prime targets for

4

pharmaceutical intervention in many disorders. There are
presently few highly selective pharmaceuticals available
for treatment of such disorders. There is therefore a
great need for drugs useful for the prevention or
5   treatment of receptor-mediated disorders, and for the
selective targeting of receptor/transporter functions, to
aid in the treatment of commonly occurring and highly
prevalent diseases.

10   Brief Description of the Drawings
          The invention, as exemplified by preferred
embodiments, is described with reference to the
accompanying drawings in which:
          Figure 1 shows a two dimensional representation of
15   the seven membrane-spanning domains of the D2 dopamine
receptor.
          Figure 2 shows a two dimensional representation of
the single membrane-spanning domain of the epidermal
growth factor receptor.
20   Figures 3A to 3G show immunoblots of isolated
dopamine receptors after various treatments, monomers (M)
and dimers (D) being indicated by arrows.
          Figure 3A shows the effect of the indicated
concentrations of D2-TM VI peptide (aa 375-394) on the
25   electrophoretic pattern of the D2 receptor (Lanes 1-4:
0, 1.3, 1.6 and 2.5 mg/ml D2-TM VI peptide,
respectively).
          Figure 3B shows the effect of the indicated
concentrations of D2-TM VII peptide (aa407-426) on the D2
30   receptor (Lanes 1-7: 0, 0.3, 0.6, 1.0, 1.3, 1.6 and 2.5
mg/ml D2-TM VII peptide).
          Figure 3C shows the effect of incubation with the
D2-TM VI and D2-TM VII peptides on the D2 receptor from
human caudate nucleus. Lanes 1 and 3: buffer control;

5

lane 2: D2-TM VI peptide; lane 4: D2-TM VII peptide.

Figure 3D shows the effect of hydrophilic and
hydrophobic receptor peptides on a D2 receptor
preparation. D2 receptors were incubated in peptide

5   buffer (lane 1); D2-C IIIA peptide (aa 244-263) (lane 2);
D2-C IIIB peptide (aa 284-303) (lane 3); β2-AR TM VI
peptide (aa 276-296) (lane 4); D1-C IIIA peptide (aa 369-
383) (lane 5); and D1-C IIIB peptide (aa 416-431) (lane
6).

10   Figure 3E shows the effect of D2-TM VII peptide on
c-myc epitope-tagged human dopamine D1 receptor and c-myc
epitope-tagged human serotonin 5-HT1B receptor. D1
receptors were incubated in peptide buffer without (lane
1) or with (lane 2) D2-TM VII peptide, and 5-HT1B

15   receptors were incubated in peptide buffer without (lane
3) or with (lane 4) D2-TM VII peptide.

Figure 3F shows the effect of temperature on the D2
dopamine receptor.

Figure 3G shows the effect of pH on the D2 dopamine

20   receptor (GAA = glacial acetic acid).

Figure 4 shows the dose-dependent inhibition of
[^{3}H]spiperone binding to membranes prepared from D2
receptor-expressing Sf9 cells by various receptor
subtype-specific peptides. The peptides tested were:

25   D2-TM 7 (TWLGYVNSA) (▲), D2-TM 5 (PAFVVYSSIVSFYVPFIVTL)
(Δ), GABA-TM (GIFNLVYW)(□), V2-TM7 (LMLLASLNSCTNPWIY)(■)
and DAT-TM12 (ALGWIIATS) (o). The effect of various
concentrations of peptides is shown as an average
percentage of the total [^{3}H]spiperone binding from 2 or

30   more independent experiments.

Figure 5 shows the dose-dependent competition
displacement of agonist [^{3}H]quinpirole binding (shown as
percentage of total [^{3}H] quinpirole binding) to membranes
prepared from D2 receptor-expressing Sf9 cells by D2

6

receptor antagonist spiperone (o) and D2-TM 7 peptide, TWLGYVNSA (•).

Figure 6 shows D2 receptor mediated dose-dependent dopamine activation of [^{35}S]GTPγS binding (left panel), and the dose-dependent inhibition of dopamine activation of [^{35}S]GTPγS binding by the D2 antagonists, spiperone (shaded bar) and D2-TM 7 peptide (TWLGYVNSA) (open bar) (right panel). D2 receptor mediated dopamine activation of [^{35}S]GTPγS binding (left panel) is shown as a percent of baseline activity, and the inhibition of dopamine activation of [^{35}S]GTPγS binding by the D2 antagonists, spiperone and D2-TM 7 peptide (TWLGYVNSA) (right panel) is shown as a percentage of the maximal response.

Figure 7 shows D2 receptor mediated dose-dependent dopamine activation of [^{35}S]GTPγS binding (left panel), and the dose-dependent inhibition of dopamine activation of [^{35}S]GTPγS binding by the D2-TM 7 peptide (TWLGYVNSA) (open bar) and the GABA-TM peptide (GIFNLVYW) (solid bar) (right panel). D2 receptor mediated dopamine activation of [^{35}S]GTPγS binding (left panel) is shown as a percent of baseline activity, and the inhibition of dopamine activation of [^{35}S]GTPγS binding by the D2-TM 7 peptide and GABA-TM peptide (right panel) is shown as a percentage of the maximal response. The values shown are the average from 2 or more independent experiments.

Figure 8 shows the effect of co-expression of a D2-TM7 peptide and the full length D2 receptor on D2 receptor density in COS cells, estimated by spiperone binding. Co-expression of a D2-TM7 peptide and the D2 receptor (o) was compared with expression of the full length D2 receptor alone (•). A representative of two independent experiments is shown.

7

Figure 9 shows the effect of coexpression of a D2-TM7 peptide with full length D2 receptors on D2 receptor function in COS cells (shaded bar) compared with expression of the full length D2 receptor alone.

5   Figures 10A to 10C show the duration (X axis) and extent (Y axis) of asymmetric body response of a rat after unilateral (left) intrastriatal injection of D2-TM VII peptide (LYSAFTWLGYVNSAVNPIIY), 15 ng/3 µl (Fig. 10A), peptide vehicle (Fig. 10B), and β2-AR VI peptide

10   (GIIMGTFTLCWLPFFIVNIVH-COOH), 15 ng/3 µl (Fig. 10C).

Figure 11 shows the duration (X axis) and extent (Y axis) of asymmetric body response of a rat with bilateral cannulae after left intrastriatal injection of D2-TM VII peptide (TWLGYVNSA), 15 ng/3 µl (together with vehicle

15   injection into the right striatum concurrently).

Figure 12 shows immunoblots of an Ni-NTA resin-purified preparation from Sf9 cells co-expressing a c-myc epitope-tagged, β2-adrenergic receptor (-c-myc-β2AR+) and a histidine-tagged TMVII peptide of the β2-adrenergic

20   receptor (6xHis-β2AR-TMVII) probed (left panel) with monoclonal antibody 9E10 against the c-myc epitope and (right panel) with a polyclonal antibody against the poly-histidine sequence of the TMVII β2-adrenergic receptor peptide. Left lane of each panel shows

25   molecular mass standards.

Figure 13A shows the dose-dependent inhibition of [^{3}H]alprenolol binding to membranes prepared from β2-adrenergic receptor-expressing Sf9 cells by various receptor subtype-specific peptides. The peptides tested

30   were: β2AR-TM I (LLIVVGNVLVI) , β1AR-TMVII (GYANSAFNP), CCR5-TMI (LYSLVFIFGFVGN), Fo c-TM (*E. Coli* ATPase Fo c subunit: GQAIAFVLFVL) and Fo b-TM (*E. Coli* ATPase Fo b

subunit: LAAIGAAIGIGILG). Figure 13B shows the effect of
the prototypical adrenergic receptor antagonist pindolol
for comparison. Inhibition is represented as the
percentage of the total [^{3}H]alprenolol binding.

5   Figures 14A to 14H show polygraph traces of blood
pressure (Y axis: mm Hg) in a rat at indicated time
intervals (X axis) after treatment with various agents:
        Figure 14A: baseline;
        Figure 14B: 1 mg/Kg isoproterenol (β1-AR agonist);
10   Figure 14C: 500 mg LYSAFTWLGYUNSAVNPIIY-NH2 (β1-AR
TMVII peptide); Figure 14D: 1 mg/Kg isoproterenol;
          Figure 14E: baseline;
          Figure14F:1mg/Kgisoproterenol; Figure 14G: vehicle;
        Figure 14H: 1 mg/Kg isoproterenol.

15   Figures 15A to 15K show polygraph traces of blood
pressure (Y axis: mm Hg) in a rat at indicated time
intervals (X axis) after treatment with various agents:
        Figure 15A: baseline;
        Figure 15B: 5 mg/Kg phenylephrine (α1A-AR agonist);
20   Figure 15C: 500 mg FFNWLGYANSAFNP-NH2 (α1A-AR TM7
peptide); Figure 15D: 5 mg/Kg phenylephrine; Figure 15E:
saline; Figure 15F: 5 mg/Kg phenylephrine; Figure 15G:
vehicle; Figure 15H: baseline; Figure 15I: 5 mg/Kg
phenylephrine; Figure 15J: 1 mg/Kg prasozin (α1A-AR
25 antagonist); Figure 15K: 5 mg/Kg phenylephrine.
        Figure 16 shows urine output (Y axis) as a function
of time (X axis) in a representative unilaterally
nephrectomized rat under anesthesia after treatment with
vehicle (10% DMSO) in water) or V2 receptor TM VII
30 antagonist peptide, LMLLASLNSCTNPWIY, (V2 AT).
        Figures 17A and 17B show the effect of a CCR5-TM I
peptide antagonist, (CCR5-TMI: LYSLVFIFGFVGN) on HIV
infection of PBMC cells as assessed by HIV reverse

9

transcriptase activity (Figure 17A) and by HIV P24
antigen production (Figure 17B).

Figure 18 shows dose-dependent inhibition of EGF
receptor tyrosine kinase activity in solubilized membrane
5   preparations from cultured A431 cells by various
transmembrane peptides. LTVIAGLVVIF, a peptide derived
from the TM domain of the EGF-erb3 receptor (EGF-tm:
solid bars) was compared with a peptide derived from the
TM domain of the GABA-A receptor subunit, GIFNLVYW (GABA-
10 tm: open bars). Response is shown as percentage of total
EGF receptor-mediated, $^{32}P\gamma$ incorporation into a receptor-
specific substrate.

Figure 19 shows the antimicrobial effect of various
transmembrane-based peptides on *E. Coli* as assessed by
15 plating and counting growth of colonies on Luria Broth
plates. Peptides examined were GIFNLVYW (GABA-TM),
LAAIGAAIGIGILG (Fo c-TM), and GQAIAFVLFVL (Fo b-TM).

Figures 20 to 22 show the effect of intra-cerebral
(IC) injection of the peptide ALGWIIATS on dopamine
20 release (X axis) at various time intervals (Y axis) in
caudate nucleus and *nucleus accumbens* measured by *in vivo*
microdialysis in an awake rat.

Figure 20 shows the release of dopamine in striatum
as a function of time following cocaine administration (5
25 mg/Kg) with no pre-treatment (•) or with pre-treatment of
rats with IC injection of DAT-TM 12 peptide (ALGWIIATS)
15 min before cocaine administration (o). Dopamine
release is shown as a percentage of basal values.

Figure 21 shows the effect of IC injection of the
30 DAT-TM 12 peptide, ALGWIIATS, alone. Response is shown as
percentage basal striatal release as a function of time.

Figure 22 shows the release of dopamine in the
nucleus accumbens as a function of time following
cocaine administration (5 mg/Kg) with no pre-treatment

10

(•) or with pre-treatment of rats with IC injection of
DAT-TM 12 peptide, ALGWIIATS, 5 min before cocaine
administration (o). Dopamine release is reported as a
percentage of basal values.

5   Figure 23 shows the effect of a CD4-TM peptide
antagonist, LIVLGGVAGLLLF, on HIV infection of PBMC cells
as assessed by HIV P24-antigen production.

Detailed Description of the Invention

10   The inventors have shown that a peptide which has
the amino acid sequence of a hydrophobic or transmembrane
(TM) domain of an integral membrane protein, or of a
portion of a transmembrane domain, has a specific and
selective antagonistic effect on the activity or function

15 of the integral membrane protein from which it is
derived. This antagonistic effect has been shown both *in
vitro* and *in vivo*, in animal models.

        While the methods and antagonist peptides of the
invention may be utilised in advance of a complete

20 understanding of their mechanism of action, it is
hypothesised that the mechanism of the antagonism exerted
by transmembrane domain peptides is the binding of such
peptides to a transmembrane domain of the integral
membrane protein, thereby interfering with intramolecular

25 interactions which contribute to the proper three-
dimensional conformation of the integral membrane protein
monomer. It is hypothesised that the formation of a
heterodimer of the antagonist peptide and the integral
membrane protein monomer will interfere with binding of

30 the integral membrane protein with its ligand and, for
integral membrane proteins which are normally associated
as dimers, will interfere with dimer formation.

        It is predicted that all integral membrane proteins
having one or more transmembrane domains will be

11

susceptible to disruption of their function by a peptide having the amino acid sequence of any one of their own transmembrane domains. An antagonist peptide having a transmembrane amino acid sequence of a particular

5   integral membrane protein shows specificity for that protein and does not interfere with the function of closely related integral membrane proteins.

Integral membrane proteins comprise a great variety of proteins, including signal-transducing proteins such

10 as G-protein coupled receptors and tyrosine kinase receptors, transporter proteins, membrane channel proteins, immunoglobuin receptors and adhesins.

Integral membrane proteins are found in the cell membranes of prokaryotic and eukaryotic cells and also

15 within intracellular membranes in eukaryotic cells, for example the endoplasmic reticulum intracellular transporter, lysosomal membrane proteins and sialoglycoproteins. Antagonist peptides in accordance with the present invention can be used to control the

20 function of integral membrane proteins found in all these various locations.

Also included within the scope of the invention are fragments or analogues of the transmembrane amino acid sequences of an integral membrane protein which are

25 effective to antagonise the function of that protein. A fragment or analogue of a transmembrane amino acid sequence of an integral membrane protein is effective if it is a functional equivalent of the transmembrane amino acid sequence.

30 The transmembrane or membrane-spanning domains of integral membrane proteins are believed to have a helical conformation and generally comprise a sequence of about 22 to 26 amino acids. In some integral membrane proteins, the transmembrane domains adopt a barrel

12

conformation.

The antagonist peptide for a particular integral membrane protein may have the entire amino acid sequence of a transmembrane domain or may comprise a portion or
5   fragment of the transmembrane amino acid sequence.

Fragments of a transmembrane amino acid sequence may be selected by truncation of one or more amino acids from the amino terminus of the transmembrane amino acid sequence, by truncation of one or more amino acids from
10   the carboxy terminus or by truncation of one or more amino acids from both amino and carboxy termini.

As is understood by those skilled in the art, in the identification of a transmembrane amino acid sequence within the total amino acid sequence of an integral
15   membrane protein, there may be a variation of one or two amino acids in defining the termini of the transmembrane amino acid sequence, depending on the hydropathy analysis software used.

This possible variation does not limit the ability
20   of one skilled in the art to select antagonist peptides or fragments in accordance with the invention.

The present invention provides antagonist peptides which correspond to the amino acid sequence of an integral membrane protein transmembrane domain, fragments
25   of such a TM amino acid sequence and peptides which include the amino acid sequence of an integral membrane protein transmembrane domain or fragments thereof.

The present invention provides antagonist peptides comprising amino acid sequences corresponding to at least
30   four, preferably ten and more preferably from fifteen to twenty consecutive amino acids of an integral membrane protein transmembrane domain.

The amino acid sequences of the transmembrane domains of integral membrane proteins are highly

13

conserved in mammals.

The function of an integral membrane protein from a first species may be antagonised by a peptide corresponding to the amino acid sequence of one of its own transmembrane domains or may be antagonised by a functionally equivalent transmembrane domain amino acid sequence from the corresponding region of the integral membrane protein of a second species. The term "functionally equivalent" means that the sequence of the transmembrane domain of the second species need not be identical to that of the first species but need only comprise a sequence which functions biologically and/or chemically as the equivalent of the transmembrane amino acid sequence of the first species.

The present invention provides a generally applicable means of selecting a suitable specific antagonist for inhibition or reduction of the activity of a target integral membrane protein such as a receptor or transporter.

In addition to the antagonist peptides disclosed herein, one of ordinary skill in the art is enabled by the present invention to identify and prepare antagonist peptides specific for any selected integral membrane protein.

Many databases are available which contain the amino acid sequences of a large number of integral membrane proteins and some databases such as SwissProt database also list the TM domains of these proteins. For proteins whose TM domains are not listed in a database, the amino acid sequence can be subjected to hydropathic analysis, for example using a computer program such as STRIDER, to deduce the TM domain amino acid sequences.

A number of examples of antagonist peptides derived from integral membrane protein TM domains in accordance

14

with the invention are described herein in detail.
Tables 1A to 1D show examples of the G-protein coupled
receptors whose amino acid sequences can be accessed in
public databases and Table 3 shows examples of other
5   sequences available in databases.

        Guided by the present disclosure and using integral
membrane protein amino acid sequence information
available either in the scientific literature or in
databases such as GenBank or SwissProt, one of ordinary
10 skill in the art can examine the hydrophobic
transmembrane amino acid sequence or sequences of a
selected integral membrane protein and identify a
suitable amino acid sequence for an antagonist peptide
specific for that protein.

15   The present invention also enables the rational
design of specific antagonist peptides or blockers active
against the protein product of any gene predicted to
encode an integral membrane protein.

        Once the amino acid sequence of a new integral
20 membrane protein is determined, for example by cloning
and sequencing a gene or cDNA for the protein and
deducing therefrom the amino acid sequence, the amino
acid sequence can be subjected to hydropathic analysis,
as described above, to identify the TM domains. The amino
25 acid sequence of at least one transmembrane domain is
then synthesised to provide a selective peptide
antagonist of the integral membrane protein.

        Alternatively, suitable effective fragments or
analogues of a transmembrane amino acid sequence may be
30 selected and screened as described herein.

        The present invention enables novel specific
pharmaceuticals for treatment of many disorders.
Selection of specific antagonist peptides in accordance
with the invention enables the development of

15

discriminating drugs with previously unavailable
selectivity and hence reduced side-effects.

For example, receptor and transporter antagonists
may be used to treat disorders associated with specific
5   receptor overactivity such as schizophrenia which is
associated with overactivity of the D2 dopamine receptor,
or may be used to indirectly restore homeostasis in
disorders which do not directly involve aberrant function
of the particular receptor or transporter. Examples of
10   disorders and antagonists in the latter category include:
anti-D1 dopamine receptor for drug abuse, anti-histamine
receptor for peptic ulcer disease, anti-angiotensin
receptor for hypertension and anti-β adrenergic receptor
for glaucoma.

15   Using the D2 dopamine receptor as a model for other
membrane spanning receptors, the inventors have shown a
dopamine antagonist effect *in vivo*, in a rat model of
rotational locomotion, by administering directly into the
caudate nucleus of the brain a peptide comprising a
20   fragment of one of the transmembrane amino acid sequences
of the D2 dopamine receptor. Most importantly, the
inventors have demonstrated specificity, with no
disruption of other closely related receptors by the
peptide designed for the D2 dopamine receptor.

25   In a further animal model, the inventors have shown
that a peptide comprising a portion of a transmembrane
domain of the β1-adrenergic receptor inhibited the
function of that receptor, and a peptide comprising a
portion of a transmembrane domain of the α1A-adrenergic
30   receptor inhibited the function of that receptor, as
evidenced by the effect of these peptides on cardiac
function and blood pressure.

The models described herein are not, however,
limited to GPCRS. The inventors have shown, for example,

that specific antagonists can be prepared, in accordance
with the invention, for tyrosine kinase receptors and
immune receptors.

Antagonist peptides in accordance with the invention
5   have also been demonstrated to interfere with the
function of mammalian receptors employed by viruses to
attack mammalian cells, as exemplified by the inhibition
of HIV infectivity by peptides derived from the TM
domains of the CCR5 and CD4 receptors.

10   In accordance with a further embodiment, the
inventors have shown the applicability of the invention
to prokaryotic systems, with the demonstration of the
anti-bacterial effect of antagonist peptides derived from
a bacterial energy-dependent transporter.

15   Antagonist peptides in accordance with the invention
may be prepared by any suitable peptide synthetic method.

Chemical synthesis may be employed, for example
standard solid phase peptide synthetic techniques may be
used. In standard solid phase peptide synthesis,
20   peptides of varying length can be prepared using
commercially available equipment. This equipment can be
obtained from Applied Biosystems (Foster City, CA.). The
reaction conditions in peptide synthesis are optimized to
prevent isomerization of stereochemical centres, to
25   prevent side reactions and to obtain high yields. The
peptides are synthesized using standard automated
protocols, using t-butoxycarbonyl-alpha-amino acids, and
following the manufacturer's instructions for blocking
interfering groups, protecting the amino acid to be
30   reacted, coupling, deprotecting and capping of unreacted
residues. The solid support is generally based on a
polystyrene resin, the resin acting both as a support for
the growing peptide chain, and as a protective group for
the carboxy terminus. Cleavage from the resin yields the

17

free carboxylic acid. Peptides are purified by HPLC techniques, for example on a preparative C18 reverse phase column, using acetonitrile gradients in 0.1% trifluoroacetic acid, followed by vacuum drying.

5   Antagonist peptides may also be produced by recombinant synthesis. A DNA sequence encoding the desired peptide is prepared, for example by cloning the required fragment from the DNA sequence encoding the complete receptor, obtainable from genomic DNA or from

10   commercially available genomic or cDNA libraries, and subcloning into an expression plasmid DNA. Suitable mammalian expression plasmids include pRC/CMV from Invitrogen Inc. The gene construct is expressed in a suitable cell line, such as a Cos or CHO cell line and

15   the expressed peptide is extracted and purified by conventional methods. Suitable methods for recombinant synthesis of peptides are described in "Molecular Cloning" (Sambrook, Fritsch and Maniatis, Cold Spring Harbor Laboratory Press, 1989).

20   Analogues of a transmembrane amino acid sequence of an integral membrane protein may be prepared by similar synthetic methods. The term "analogue" extends to any functional and/or chemical equivalent of a transmembrane amino acid sequence and includes peptides having one or

25   more conservative amino acid substitutions, peptides incorporating unnatural amino acids and peptides having modified side chains.

Examples of side chain modifications contemplated by the present invention include modification of amino

30   groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with $NaBH_4$; amidation with methylacetimidate; acetylation with acetic anhydride; carbamylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6,

18

trinitrobenzene sulfonic acid (TNBS); alkylation of amino
groups with succinic anhydride and tetrahydrophthalic
anhydride; and pyridoxylation of lysine with pyridoxal-
5'-phosphate followed by reduction with NaBH$_4$.

5   The guanidino group of arginine residues may be
modified by the formation of heterocyclic condensation
products with reagents such as 2, 3-butanedione,
phenylglyoxal and glyoxal.

        The carboxyl group may be modified by carbodiimide
10   activation via -acylisourea formation followed by
subsequent derivatisation, for example, to a
corresponding amide.

        Sulfhydryl groups may be modified by methods such as
carboxymethylation with iodoacetic acid or iodoacetamide;
15   performic acid oxidation to cysteic acid; formation of
mixed disulphides with other thiol compounds; reaction
with maleimide, maleic anhydride or other substituted
maleimide; formation of mercurial derivatives using 4-
chloromercuribenzoate, 4-chloromercuriphenylsulfonic
20   acid, phenylmercury chloride, 2-chloromercuric-4-
nitrophenol and other mercurials; carbamylation with
cyanate at alkaline pH.

        Tryptophan residues may be modified by, for example,
oxidation with N-bromosuccinimide or alkylation of the
25   indole ring with 2-hydroxy-5-nitrobenzyl bromide or
sulphonyl halides. Tyrosine residues may be altered by
nitration with tetranitromethane to form a 3-
nitrotyrosine derivative.

        Modification of the imidazole ring of a histidine
30   residue may be accomplished by alkylation with iodacetic
acid derivatives of N-carbethoxylation with
diethylpyrocarbonate.

        Examples of incorporating unnatural amino acids and
derivatives during peptide synthesis include, but are not

19

limited to, use of norleucine, 4-amino butyric acid, 4-
amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic
acid-, t-butylglycine, norvaline, phenylglycine,
ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic

5   acid, 2-thienyl alanine and/or D-isomers or amino acids.

Examples of conservative amino acid substitutions
are substitutions within the following five groups of
amino acids (amino acids are identified by the
conventional single letter code): Group 1: F Y W; Group

10 2: V L I; Group 3: H K R; Group 4: M S T P A G; Group 5:
D E.

Fragments or analogues of the antagonist peptides of
the invention may be conveniently screened for their
effectiveness as receptor antagonists, for example by

15 examining their ability to inhibit ligand-binding by the
relevant receptor which has been pre-incubated with the
peptide. Ligand-binding inhibition can be determined, for
example, by a soluble receptor radioligand binding assay,
as described herein.

20   The antagonist peptides may also be screened for
their effectiveness as receptor antagonists by examining
their ability to impair receptor coupling to second
messenger systems or their ability to impair some
functional activity. For example, for a GPCR such as the

25 D2 dopamine receptor, the ability of the antagonist to
block D2 receptor mediated attenuation of adenylyl
cyclase activity provides a convenient index of efficacy
as described herein.

For a tyrosine kinase receptor such as the EGF

30 receptor, the ability of antagonists to inhibit EGF
receptor tyrosine phosphorylation, as described herein,
provides an index of efficacy.

The peptide antagonists of the invention may be
administered therapeutically by injection or by oral,

20

nasal, buccal, rectal, vaginal, transdermal or ocular
routes in a variety of formulations, as is known to those
in the art.

For oral administration, various techniques can be
5   used to improve stability, based for example on chemical
modification, formulation and use of protease inhibitors.
Stability can be improved if synthetic amino acids are
used, such as peptoids or betidamino acids, or if
metabolically stable analogues are prepared.

10   Formulation may be, for example, in water/oil
emulsion or in liposomes for improved stability. Oral
administration of peptides may be accompanied by protease
inhibitors such as aprotinin, soybean trypsin inhibitor
or FK-448, to provide protection for the peptide.

15   Suitable methods for preparation of oral formulations of
peptide drugs have been described, for example, by
Saffran et al., 1979) (use of trasylol protease
inhibitor); Lundin et al. (1986) and Vilhardt et al.,
(1986).

20   Due to the high surface area and extensive vascular
network, the nasal cavity provides a good site for
absorption of both lipophilic and hydrophilic drugs,
especially when coadministered with absorption enhancers.
The nasal absorption of peptide-based drugs can be
25   improved by using aminoboronic acid derivatives,
amastatin, and other enzyme inhibitors as absorption
enhancers and by using surfactants such as sodium
glycolate, as described in Amidon et al., (1994).

The transdermal route provides good control of
30   delivery and maintenance of the therapeutic level of drug
over a prolonged period of time. A means of increasing
skin permeability is desirable, to provide for systemic
access of peptides. For example, iontophoresis can be
used as an active driving force for charged peptides or

21

chemical enhancers such as the nonionic surfactant n-decylmethyl sulfoxide (NDMS) can be used.

Transdermal delivery of peptides is described in Amidon et al. (1994) and Choi et al. (1990).

5   Peptides may also be conjugated with water soluble polymers such as polyethylene glycol, dextran or albumin or incorporated into drug delivery systems such as polymeric matrices to increase plasma half-life.

More generally, formulations suitable for particular
10   modes of administration of peptides are described, for example, in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Company (Easton, PA.)

The peptide antagonists of the invention also provide a tool for the elucidation of the function of
15   many important orphan receptors whose structures and locations are known but for which the endogenous ligand is unknown. Disruption of the function of an orphan receptor by a transmembrane peptide antagonist and observation of the resulting loss or disruption of
20   function will assist in elucidating the role of the orphan receptor.

The present invention also provides new methods of tissue imaging. An antagonist peptide derived from the transmembrane amino acid sequence of a membrane-spanning
25   protein may be labelled with a suitable signalling moiety, such as an imaging radionuclide, and administered *in vivo*. The labelled peptide binds stably to the receptor permitting visualisation and quantification of the receptor. Suitable radionuclides include
30   technetium^{99}, thallium, ^{11}C or ^{18}F.

Peptides may be labelled by conventional methods known to those skilled in the art.

The specificity of the antagonist peptides of the invention for the receptor will provide improved accuracy

22

and precision in the determination of receptor
localisation and receptor density on cells and in
tissues. Detection of the signalling moiety and
therefore of the bound receptor can be carried out by
5   conventional methods suitable for each particular
labelling moiety.

In a further embodiment, the invention provides new
methods for gene therapy utilising a genetically
engineered, recombinant nucleotide sequence encoding a
10 peptide antagonist, incorporated in a suitable
transfection vector for introduction of the coding
sequence into a selected cell or tissue, either *ex vivo*
or *in vivo*, in order to provide for *in vivo* production of
a selected integral membrane protein antagonist. For
15 example, adenovirus and vaccinia virus are employed as
vectors for gene therapy. Gene therapy techniques are
reviewed, for example, in (Hanania, E.G. (1995), *Am. J.
of Med.*, v. 99, pp. 537-552). A recombinant nucleotide
sequence encoding an antagonist peptide of the invention
20 may be incorporated into a transfection vector under the
control of a tissue-specific promoter which ensures
expression of the nucleotide sequence only in the
selected target tissue. For example, a viral vector may
be employed incorporating a promoter which directs
25 expression only in brain cells which have dopamine D2
receptors and a nucleotide sequence encoding an
antagonist peptide specific for the dopamine D2 receptor.
For treatment of a disorder associated with over-
activity of dopamine receptors, the viral preparation can
30 be introduced directly into the brain, for example by
intra-cerebroventricular injection or infusion, where the
virus is taken up by brain cells, but the peptide is
produced only where required. Non-viral gene therapy
methods are described, for example, in EP 289034.

23

In a further embodiment, the invention provides
transgenic animal models expressing transmembrane peptide
antagonists which modulate endogenous integral membrane
protein function. These animal models will provide a
5   tool for testing the design, efficacy and toxicology of
integral membrane protein antagonist peptides and will
also provide models that mimic clinical diseases.

Transgenic animal models in accordance with the
invention can be created by introducing a DNA sequence
10   encoding a selected peptide antagonist either into
embryonic stem (ES) cells of a suitable animal, for
example a mouse, by transfection or microinjection, or
into a germ line or stem cell by a standard technique of
oocyte microinjection.

15   The ES cells are inserted into a young embryo and
this embryo or an injected oocyte are implanted into a
pseudo-pregnant foster mother to grow to term.

The techniques for generating transgenic animals are
now widely known and are described in detail, for
20   example, in Hogan et al., (1986), and M. Capecchi (1989).

1.   **PEPTIDE ANTAGONISTS FOR G-PROTEIN COUPLED RECEPTORS**

The G-protein coupled receptors have a common
pattern of seven hydrophobic membrane-spanning domains.
25   These receptors are involved in a wide variety of
pathways. Table 1 lists the various receptors which
belong to this superfamily.

(a)   Dopamine Receptor Antagonists

In accordance with one embodiment of the present
30   invention, dopamine receptor antagonist peptides and a
method for regulating or inhibiting the activity of a
selected dopamine receptor are provided.

Five distinct dopamine receptors have been
identified and are designated D1 to D5 (Seeman, P.

24

(1995). All belong to the family of G protein-coupled receptors (GPCRs) that have seven highly conserved membrane spanning regions which are linked by intracellular and extracellular loops (O'Dowd, 1993).

5   Comparison of the primary structure of GPCRs shows that the greatest similarity exists in the transmembrane domains, whereas greatest differences are found within the N- and C-terminal regions and the cytoplasmic third loop connecting transmembrane domains V and VI. For

10 instance, D1 and D5 receptors have a shorter third intracellular loop and a longer carboxyl tail compared to D2, D3, and D4 receptors.

One of ordinary skill in the art is enabled by this invention to identify specific antagonist compounds which

15 regulate or inhibit each of the dopamine receptors.

(i)   Dopamine D2 receptor antagonists

The following description of the dopamine D2 receptor and of peptide antagonists of that receptor provides a general illustration of the selection of a

20 specific antagonist peptide to an integral membrane protein, in accordance with the invention. The same method may be applied by one of ordinary skill in the art to select an antagonist to any selected integral membrane protein.

25 The dopamine D2 receptor is activated by the neurotransmitter, dopamine, leading to the inhibition of intracellular adenylate cyclase.

The D2 receptor gene encodes a long and a short form of the receptor, differing by a 29 amino acid segment in

30 the third intracellular loop. The long and short forms have identical transmembrane domains.

Figure 1 shows a two-dimensional representation of the D2 dopamine receptor spanning the cell membrane. The seven transmembrane domains and two cytoplasmic domains

are identified, the transmembrane amino acid sequences
being boxed.

Table 2 shows the information available in the
SwissProt database for the dopamine D2 receptor,
5   Accession No. P14416 (Sequence ID NO:8).

The transmembrane (TM) domains are identified by
amino acid number, as follows:

      TM 1   amino acids 38 to 60
      TM 2   amino acids 72 to 97
10   TM 3   amino acids 109 to 130
      TM 4   amino acids 152 to 174
      TM 5   amino acids 187 to 210
      TM 6   amino acids 374 to 397
      TM 7   amino acids 406 to 429

15   The amino acid sequences of these transmembrane
domains can be determined from the complete amino acid
sequence provided. Any one of these transmembrane amino
acid sequences may be selected for use as a specific
antagonist of the D2 dopamine receptor. A D2 dopamine
20 receptor antagonist peptide may, therefore, be selected
from the following transmembrane amino acid sequences:

      TM I   ATLLTLLIAVIVFGNVLVCMAVS (Sequence ID NO:1)
      TM II   LIVSLAVADLLVATLVMPWVVYLEVV (Sequence ID NO:2)
      TM III IVFTLDVMMCTASILNLCAISI (Sequence ID NO:3)
25   TM IV   VTVMISIVWVLSFTISCPLLFGL (Sequence ID NO:4)
      TM V   PAFVVYSSIVSFYVPFIVTLLVYI (Sequence ID NO:5)
      TM VI   MLAIVLGVFIICWLPFFITHILN (Sequence ID NO:6)
      TM VII VLYSAFTWLGYVNSAVNPIIYTTF (Sequence ID NO:7)
or may be an effective fragment or analogue of any of
30 these sequences.

D2 receptors are found in brain, where the highest
densities have been found in the striatum (Caudate-
putamen, nucleus accumbens), olfactory tubercle, and
substantia nigra and pituitary, whereas lower densities

26

are present in the cortex, hippocampus and limbic brain regions (Bouthenet et al., 1987, 1991, Mansour et al., 1990). At the cellular level, D2-like receptors have been identified on synaptic nerve terminals, and there is

5   evidence that D2 receptors are colocalized with D1 receptors in certain neuronal populations (Surmeier et al., 1992). These mapping studies also indicate a pre-synaptic localization of D2-like receptors where they may function as autoreceptors regulating the synthesis and/or

10   release of dopamine (Starke et al., 1989, Sokoloff et al., 1990).

In accordance with the invention, the following peptides based on the D2 dopamine receptor TM domains have been synthesised: D2-TM I: YATLLTLLIAVIVFGNVLVC

15   (Sequence ID NO:61);

D2-TM II: VSLAVADLLVATLVMPWVVY (Sequence ID NO:60);
D2-TMIII:TLDVMMCTASILNLCAISID (Sequence ID NO:59);
D2-TM IV: RVTVMISIVWVLSFTISCPL (Sequence ID NO:58);
D2-TM V: PAFVVYSSIVSFYVPFIVTL (Sequence ID NO:57);

20   D2-TM VI: LAIVLGVFIICWLPFFITHI (Sequence ID NO:56);
D2-TM VII: LYSAFTWLGYVNSAVNPIIY (Sequence ID NO:55);
D2-TM VII: TWLGYVNSA (Sequence ID NO:64).

As described in Examples 1 to 3, the inventors have shown that peptides of amino acid sequence corresponding

25   to all or a portion of a D2 receptor TM domain are highly specific antagonists of D2 receptor binding and function *in vitro* and *in vivo*.

(ii) Dopamine D1 and D3 to D5 receptor antagonists

The dopamine D1 and D3 to D5 receptors are also

30   receptors for the neurotransmitter dopamine and are found in brain as well as in other tissues.

The amino acid sequences of these receptors, and identification of their transmembrane domains, can be obtained, for example, from SwissProt Database under the

Accession Numbers listed in Table 1.

Using this information, one skilled in the art can readily ascertain the transmembrane amino acid sequences for each of these dopamine receptors and can thereby
5   synthesise antagonist peptides suitable and specific for each receptor. For example, for the D1 dopamine receptor, an antagonist peptide may be selected from the following transmembrane amino acid sequences or may be an effective fragment or analogue of any of these sequences:
10   TM 1: ILTACFLSLLILSTLLGNTLVCAAV (Sequence ID NO:9);
             TM 2: FFVISLAVSDLLVAVLVMPWKAVAEIA (Sequence ID NO:10);
             TM 3: NIWVAFDIMCSTASILNLCVISVD (Sequence ID NO:11);
             TM 4: AAFILISVAWTLSVLISFIPVQLSW (Sequence ID NO:12);
             TM 5:   TYAISSSVISFYIPVAIMIVTYTRI (Sequence ID NO:13);
15   TM 6: TLSVIMGVFVCCWLPFFILNCILPFC (Sequence ID NO:14);
             TM 7: FDVFVWFGWANSSLNPIIYAFNAD (Sequence ID NO:15).

The D1 dopamine receptor has been associated with drug abuse and the D3 and D4 receptors have been associated with schizophrenia. Antagonists of these
20   receptors in accordance with the invention provide specific therapeutic agents for use in these conditions.

(b) Adrenergic Receptor Antagonists

In accordance with a further embodiment of the invention, adrenergic receptor antagonist peptides and a
25   method for regulating or inhibiting the activity of a selected adrenergic receptor are provided.

The adrenergic receptors (AR) mediate the effects of the catecholamines epinephrine and norepinephrine on a wide variety of physiologic processes, such as regulation
30   of blood pressure and heart rate.

Molecular cloning studies have now shown that the physiological actions of epinephrine and norepinephrine are mediated by the products of at least nine types of AR. These receptors can be subdivided into three groups,

28

each capable of coupling to different G proteins. β_1-, β_2-, and β_3AR are involved in the activation of adenylyl cyclase. Conversely, activation of the platelet and kidney α_2AR (α_2AR-C10 and α_2AR-C4, respectively) inhibits

5   adenylyl cyclase activity via the intermediacy of the G protein G_i. The α_1 AR receptors (α_{1A} and α_{1B}) have the ability to stimulate phospholipase C. Stimulation of this effector enzyme leads to membrane phospholipid hydrolysis and the subsequent mobilization of calcium

10   from intracellular stores.

The various AR, and the respective G proteins to which they couple, provide the means by which the two adrenergic agonists epinephrine and norepinephrine can elicit many different intracellular responses.

15   For example, for the β1-adrenergic receptor, an antagonist peptide may be selected from the following transmembrane amino acid sequences or may be an effective fragment or analogue of any of these sequences:

TM I : GMGLLMALIVLLIVAGNVLVIVAI (Sequence ID NO:16);

20   TM II: IMSLASADLVMGLLVVPFGATIVV (Sequence ID NO:17);

TM III:ELWTSVDVLCVTASIETLCVIALD (Sequence ID NO:18);

TM IV: RGLVCTVWAISALVSFLPILMHWW (Sequence ID NO:19);

TM V : RAYAIASSVVSFYVPLCIMAFVYL (Sequence ID NO:20);

TM VI: LGIIMGVFTLCWLPFFLANVVKAF (Sequence ID NO:21);

25   TM VII:RLFVFFNWLGYANSAFNPIIYCRS (Sequence ID NO:22).

For example, for the β2-adrenergic receptor, an antagonist peptide may be selected from the following transmembrane amino acid sequences or may be an effective fragment or analogue of any of these

30   sequences:

TM I: TAGMGLLMALIVLLIVAGNVLVIVAI (Sequence ID NO:65);

TM II: LFIMSLASADLVMGLLVVPFGATIVV (Sequence ID NO:66);

TM III: WTSVDVLCVTASIETLCVIALD (Sequence ID NO:67);

TM IV: ARGLVCTVWAISALVSFLPILMHW (Sequence ID NO:68);
TM V: RAYAIASSVVSFYVPLCIMAFVYL (Sequence ID NO:69);
TM VI: TLGIIMGVFTLCWLPFFLANVVKA (Sequence ID NO:70);
TM VII: DRLFVFFNWLGYANSAFNPIIYC (Sequence ID NO:71).

For example, for the α1A-adrenergic receptor, an antagonist peptide may be selected from the following transmembrane amino acid sequences or may be an effective fragment or analogue of any of these sequences:

TM I: GVGVGFLAAFILMAVAGNLLVILSV (Sequence ID NO:23);
TM II: FIVNLAVADLLLSATVLPFSATMEVL (Sequence ID NO:24);
TM III: DVWAAVDVLCCTASILSLCTISV (Sequence ID NO:25);
TM IV: AAILALLWVVALVVSVGPLLGWKEP (Sequence ID NO:26);
TM V: AGYAVFSSVCSFYLPMAVIVVMYC (Sequence ID NO:27);
TM VI: LAIVVGVFVLCWFPFFFVLPLGSL (Sequence ID NO:28);
TM VII: EGVFKVIFWLGYFNSCVNPLIYPCS (Sequence ID NO:29).

The inventors have shown that the peptides FFNWLGYANSAFNP (Sequence ID NO:30) and GYANSAFNP (Sequence ID NO:72), both fragments of the TM VII domain of the human β1-adrenergic receptor, inhibited the function of that receptor *in vitro* and *in vivo*, as described in Examples 4 and 5.

The inventors have also shown that the peptides VFKVIFWLGYFNSCVN (Sequence ID NO:31) and VFKVIFWLGYFNS (Sequence ID NO:73), both fragments of the TM VII domain of the human α1A-adrenergic receptor, inhibited the function of that receptor *in vivo*, as shown in Example 5.

Adrenergic receptor antagonists are accepted therapeutic agents for treatment of hypertension. The adrenergic receptor antagonist peptides of the present invention provide new agents with previously unavailable specificity for use in treatment of hypertension.

(c) Adenosine Receptor Antagonists

In accordance with a further embodiment of the

invention, adenosine receptor antagonist peptides and a
method for regulating or inhibiting the activity of a
selected adenosine receptor are provided.

　　　　Adenosine is a neuromodulator which is released in
5　　response to increased activity or stress.

　　　　Adenosine receptors are found in both central and
peripheral neural locations. Four subtypes of adenosine
receptors, designated A1, A2a, A2b and A3, have been
identified.

10　　　　In general, adenosine exerts a depressant action in
the brain, heart and kidneys by activating adenosine
receptors. The depressant action in the brain is
believed to confer neuroprotection. Moreover, centrally
acting adenosine has been shown to be involved in pain,
15　　cognition, movement and sleep. Peripherally, adenosine
is believed to have arrhythmic, hypotensive and
antilipolytic properties.

　　　　The antiasthmatic effects of theophylline and the
antidepressant and cognition-enhancing effects of
20　　caffeine are attributed to their action as adenosine
receptor antagonists.

　　　　Adenosine receptor antagonists have a role as
therapeutics in the treatment of cardiovascular, renal
and central nervous system disorders and are likely to be
25　　useful as anti-asthmatics, anti-depressants, anti-
arrhythmics, anti-Parkinsonian therapeutics, cognitive
enhancers and as renal protective agents.

(d) Vasopressin type 2 receptor antagonists

　　　　In accordance with a further embodiment of the
30　　invention, vasopressin type 2 receptor antagonist
peptides and a method for regulating or inhibiting the
activity of the receptor are provided.

　　　　The vasopressin type 2 (V2) receptor of the kidney
collecting tubules binds arginine vasopressin, leading to

31

G protein-mediated activation of adenylate cyclase and decreased water permeability of the tubule cells, resulting in fluid retention by the kidney. Defects in the V2 receptor are a cause of congenital nephrogenic

5   *diabetes insipidus*, characterized by excessive urine excretion (polyuria) and failure to concentrate urine in response to vasopressin.

Currently there are few selective pharmaceutical agents that target this important receptor protein.

10   For the V2 receptor, an antagonist peptide may be selected from the following transmembrane amino acid sequences or may be an effective fragment or analogue of any of these sequences:

TMI: AELALLSIVFVAVALSNGLVLAALA (Sequence ID NO:74);

15   TMII: IGHLCLADLAVALFQVLPQLAW (Sequence ID NO:75);

TMIII: AVKYLQMVGMYASSYMILAMTL (Sequence ID NO:76);

TMIV: VLVAWAFSLLLSLPQLFIFAQ (Sequence ID NO:77);

TMV: TYVTWIALMVFVAPTLGIA (Sequence ID NO:78);

TMVI: MTLVIVVVYVLCWAPFFLVQLW (Sequence ID NO:79);

20   TMVII: LLMLLASLNSCTNPWIYASF (Sequence ID NO:80).

Antagonist peptides based on the amino acid sequence of the TM domains of the V2 Receptor, in accordance with the invention, provide therapeutic agents which can reduce or prevent the function of that receptor,

25   providing a potent diuretic for the management of hypertension, congestive heart failure and other fluid retentive disorders.

The inventors have shown that the peptide LMLLASLNSCTNPWIY (Sequence ID NO:53), a fragment of the

30   TM VII domain of the V2 receptor, by inhibition of the V2 receptor, acted as a diuretic in the intact rat, as described in Example 6.

(e) Chemokine receptor antagonists

In accordance with a further embodiment of the

32

invention, chemokine receptor antagonist peptides and a
method for regulating or inhibiting the activity of a
selected chemokine receptor are provided.

The cell surface receptors for chemokines belong to
5   the family of G protein coupled receptors, and have been
implicated in a number of physiological functions.

One of the major steps leading to HIV infection of
mammalian cells involves virus interaction with two
receptors belonging to the family of G protein coupled
10 receptors, namely (i) the cell surface single TM-spanning
CD4 receptor and (ii) the seven-TM chemokine receptors
(such as CCR5 and CXCR4, also called fusin), in order for
the virus to gain access to the cell. The chemokine
receptors, CCR5 and CXCR4, have been identified as the
15 main cofactors necessary for HIV entry into CD4-positive
cells(Dragic et al., (1996); Weiss et al., (1996)). The
phenotype of the HIV virus determines whether it
preferentially uses CXCR4 or CCR5, or sometimes both
receptors, for entry into CD4-positive cells. CCR2B and
20 CCR3 are minor co-factors for HIV entry.

(i)   Antagonists for the CCR5, CXCR4, CCR2B and CCR3
receptors

For the CCR5 receptor or the CXCR4 receptor, an
antagonist peptide may be selected from the transmembrane
25 amino acid sequences of these receptors shown in Table 4
or may be an effective fragment or analogue of any of
these sequences. Similarly, an antagonist peptide based
on the transmembrane domain of the CCR2B or CCR3 receptor
can be used to block HIV entry, as these receptors may
30 also act as coreceptors with the CD4 receptors for HIV
virus entry.

The inventors have shown that the peptide
LYSLVFIFGFVGN (Sequence ID NO:82), a fragment of the TM I
domain of the CCR5 receptor, inhibited HIV infection of

33

human PBMC cells, as described in Example 7.

An antagonist peptide based on the amino acid sequence of any one of the TM domains of the CCR5 receptor, the CXCR4 receptor or the CCR2B or CCR3

5   receptors, in accordance with the invention, provides a therapeutic agent which can disrupt the function of the respective receptor, thereby preventing entry of the HIV virus into CD4-positive cells containing that receptor. Such therapeutic agents may be used prophylactically or

10   after exposure to the HIV virus.

(f)   Serotonin Receptor Antagonists

In accordance with a further embodiment of the invention, serotonin receptor antagonist peptides and a method for regulating or inhibiting the activity of a

15   selected serotonin receptor are provided.

The diverse biological activities of the neurotransmitter, serotonin, are mediated through a variety of serotonin receptors now numbering 15. All except the 5HT3 receptor belong to the superfamily of

20   GPCRs.

Serotonin has been associated with a number of neuropsychiatric disorders such as depression, consummatory disorders and drug addiction, migraine and other vascular disorders.

25   For example, for the 5-HT1A serotonin receptor, an antagonist peptide may be selected from the transmembrane amino acid sequences of the receptor shown in Table 4 or may be an effective fragment or analogue of any of these sequences.

30   An antagonist peptide based on the amino acid sequence of a transmembrane domain of any serotonin receptor, in accordance with the invention, provides a therapeutic agent which can disrupt the function of that receptor and hence can be used for specific directed therapy in

34

neuropsychiatric disorders such as depression,
consummatory disorders and drug addiction, migraine and
other vascular disorders.

(g) Mu-opioid Receptor Antagonists

5   In accordance with a further embodiment of the
invention, opioid receptor antagonist peptides and a
method for regulating or inhibiting the activity of a
selected opioid receptor are provided.

The diverse biological activities of the endogenous
10   opioid peptides are mediated through a variety of opioid
receptors including Mu, Delta, and Kappa.

Opioid neuronal systems play important roles in a
wide variety of physiological processes including pain,
mood, learning, thermoregulation, ingestive behaviour,
15   motor activity and the perception of reward, with
critical effects in modulating endocrine, cardiovascular,
respiratory, gastrointestinal, autonomic and immune
functions.

Currently there are few selective pharmaceutical
20   agents that target these important receptor proteins.

For example, for the Mu opioid receptor (MOR), an
antagonist peptide may be selected from the transmembrane
amino acid sequences of the receptor shown in Table 4 or
may be an effective fragment or analogue of any of these
25   sequences.

An antagonist peptide based on the amino acid
sequence of the transmembrane domains of the Mu-opioid
receptor, in accordance with the invention, provides a
therapeutic agent which can disrupt the function of that
30   receptor and can be used in the treatment of disorders
including substance abuse, obesity, eating disorders and
bowel motility.

(h) Angiotensin Type 1 Receptor Antagonists

In accordance with a further embodiment of the

35

invention, angiotensin receptor antagonist peptides and a
method for regulating or inhibiting the activity of a
selected angiotensin receptor are provided.

Angiotensin II (ANG II), a component in the
5   renin-angiotensin system (RAS), is an important factor in
the pathogenesis of cardiovascular diseases including
hypertension, cardiac left ventricular hypertrophy (LVH)
and congestive heart failure. Angiotensin II also
contributes to structural alterations of the vasculature
10   such as medial hypertrophy, neointima formation and
post-infarct remodeling of the heart. The biological
activities of angiotensin II are mediated by the ANG II
AT1 and AT2 receptor subtypes which display a
heterogeneous distribution. Virtually all known
15   physiological and cardiovascular actions of ANG II have
been attributed to the AT1 receptor which is coupled to a
G-protein, while stimulation of AT2 receptors, which are
not G-protein-coupled, leads to an inhibition of cell
proliferation and possibly induces cell differentiation.
20   It is conceivable that under physiological conditions AT1
receptors facilitate, whereas AT2 receptors inhibit,
angiogenesis. Under pathophysiological conditions, such
as postmyocardial infarction or LVH, the AT2 receptor
could be upregulated to control excessive growth mediated
25   in part by the AT1 receptor.

For example, for the ANG II AT1 receptor, an
antagonist peptide may be selected from the transmembrane
amino acid sequences of the receptor shown in Table 4 or
may be an effective fragment or analogue of any of these
30   sequences.

Blockers of the angiotensin system are currently
used in hypertension, congestive heart failure and
diabetic neuropathy. Antagonist peptides based on the
amino acid sequence of a TM domain of the AT1 receptor

provide therapeutic agents which can be used in these same diseases.

(i) Neuropeptide Y 5 Receptor Antagonists

In accordance with a further embodiment of the
5 invention, neuropeptide Y5 (NPY5) receptor antagonist peptides and a method for regulating or inhibiting the activity of that receptor are provided.

Neuropeptide Y (NPY) plays important roles in the central control of appetite and energy balance. These
10 specific activities are mediated by the NPY5 receptor. The amino acid sequence deduced from rat Y5 cDNA shows only 30-33% identity to other NPY receptors, including Y1, Y2, and Y4/PP1. Pharmacological analysis shows that the Y5 receptors have high affinity for the peptides that
15 elicit feeding (e.g. NPY, PYY, (2-36)NPY, and (LP)NPY) and low affinity for nonstimulating peptides (e.g. (13-36)NPY and rat PP)(Gerald et al.(1996), Nature, 382,168).

Antagonist peptides based on the amino acid sequence
20 of the TM domains of the NPY5 receptor, provide therapeutic agents which can be.used for the management of appetite regulation in obesity, and type 2 diabetes mellitus and related conditions.

(j) Melanocyte Stimulating Hormone Receptor

25 In accordance with a further embodiment of the invention, melanocyte stimulating hormone (MSH) antagonist peptides and a method for regulating or inhibiting the activity of a selected MSH are provided.

MSH is a strong stimulator of pigment cells,
30 modulating skin colour change in some animals. MSH has also been shown to act as a neurotransmitter in the central nervous system, as an endocrine stimulant and as a modulator of immune inflammatory responses. The hormone is considered a potential tool in the diagnosis

and therapy of melanoma, as it has been used in conjugation with cytotoxin and cytotoxic T-cells for killing melanoma cells by recognizing their MSH receptors.

5   Antagonist peptides based on an amino acid sequence of a TM domain of the MSH receptor, as shown in Table 4, provide therapeutic agents which can be used for the management of hyperpigmentation, melanoma and inflammatory disorders.

10

2. PEPTIDE ANTAGONISTS OF TYROSINE KINASE RECEPTORS

In accordance with a further embodiment of the invention, tyrosine kinase antagonist peptides and a method for regulating or inhibiting the activity of a
15   selected tyrosine kinase receptor are provided.

The tyrosine kinase receptors have an amino terminus involved in ligand binding, a single membrane-spanning domain and a homologous carboxyl tail catalytic domain with intrinsic tyrosine kinase activity (Kraus et al.,
20   1989).

Examples of such tyrosine kinase receptors include receptor families for a number of growth factors, including epidermal growth factor (EGF), colony-stimulating factor 1/platelet derived growth factors and
25   insulin/insulin-like growth factor , *fibroblast growth factor, tumor necrosis factor, vascular endothelial growth factor*. Tyrosine kinase receptors are localized in a wide range of epithelial and fibroblastic cells. Tyrosine kinase receptors mediate a plethora of
30   biological activities, including regulation of cell proliferation, angiogenesis and apoptosis among others.

Binding of ligand to the extracellular portion of a tyrosine kinase receptor results in an association of two receptor molecules (dimerization) that leads to

38

conformational changes resulting in the phosphorylation
of the cytoplasmic domain of the receptor (Boni-
Schnetzler et al., 1987).

(a) Epidermal growth factor receptor antagonists

5   The epidermal growth factor (EGF) receptor has four
subtypes, identified as erb1 to erb4. A schematic
representation of an EGF receptor, with a single
membrane-spanning domain, is shown in Figure 2. The
family of EGF receptors is prototypic for the other
10   tyrosine kinase receptors.

        EGF receptors have been shown to act as oncogenes by
mechanisms of overexpression, or mutations that
constitutively activate the intrinsic tyrosine kinase
activity of these proteins (Schlessinger, J., 1986;
15   Yarden et al., 1987). In particular, the EGF-erb3
receptor is overexpressed in a subset of human mammary
tumors.

        The ability to inhibit or regulate activity of the
EGF family of receptors by the antagonist peptides of the
20   invention provides a new, specific tool to prevent the
development of, or control, of neoplastic growth in
psoriasis and cancer.

        For example, for the EGF-erb1 receptor an antagonist
peptide may have the transmembrane domain amino acid
25   sequence IATGMVGALLLLLVVALGIGLFM (Sequence ID NO:32) or
may be an effective fragment or analogue of that
sequence, and for EGF-erb3, the antagonist may be
MALTVIAGLVVIFMMLGGTFL (Sequence ID NO:83) or an effective
analogue or fragment thereof.

30   The inventors have shown that the peptide
LTVIAGLVVIF (Sequence ID NO:84), a fragment of the TM
domain of the EGF-erb3 receptor, inhibited the tyrosine
kinase function of that receptor in cultured A431 cells,
as described in Example 8. Such an antagonist peptide

39

provides a therapeutic agent for inhibition of cell
proliferation, for use , for example, in cancer,
psoriasis or hyper-keratotic disorders.

(b) Fibroblast Growth Factor receptor antagonists

5   Tyrosine kinase receptors such as Fibroblast Growth
Factor receptor, FGFr (also belonging to the
immunoglobulin superfamily), Vascular Endothelial Growth
Factor receptor, VEGFr (also belonging to the
immunoglobulin superfamily), and Platelet Derived Growth
10   Factor receptor, PDGFr, play an important role in
angiogenesis. Angiogenesis comprises the processes
leading to the generation of new blood vessels through
sprouting from already-existing blood vessels. Blood
vessel growth is associated with wound healing, tissue
15   growth and repair; abnormal angiogenesis occurs in
pathologies such as cancer and diabetic retinopathy.

Angiogenic inhibitors are of clinical significance
because they can be used to influence directly the
angiogenic processes involved, for example, in wound
20   healing. Angiogenesis inhibitors will also be of value
in treatment of diseases including pathogenic
neovascularization such as Kaposi's sarcoma, diabetic
retinopathy, and malignant tumor growth.

The Fibroblast Growth Factor receptor (FGFr) has
25   two forms, identified as FGFr1 and FGFr2.

Antagonist peptides based on the amino acid sequence
of the TM domain of the FGFr1 (IIIYCTGAFLISCMVGSVIVY:
Sequence ID NO:85) or FGFr2 (AIYCIGVFLIACMVVTVILC:
Sequence ID NO:86) receptors, provide therapeutic agents
30   which can be used to regulate angiogenesis.

(c) Vascular Endothelial Growth Factor receptor antagonists

In accordance with a further embodiment of the
invention, vascular endothelial growth factor receptor 1

40

and 2 antagonist peptides and a method for regulating or
inhibiting the activity of the selected receptor are
provided.

5   The Vascular Endothelial Growth Factor receptor
(VEGFr) has two forms, identified as VEGFr1 and VEGFr2,
with TM domains ISYSFQVARGMEFLSSRKCIH (Sequence ID NO:87)
and IIILVGTTVIAMFFWLLLVIILGTV (Sequence ID NO:88),
respectively.

(d)   Trk A receptor antagonists

10   Neurotrophins act by binding and activating membrane
receptors which belong to the trk family of protein
tyrosine kinases. Trk A is the receptor for nerve growth
factor, Trk B for brain derived neurotrpoc factor(BDNF)
and neurotrophin-4, and trk C for the neurotrophin-3

15   receptor. Trk B and trk C are abundantly expressed in
different parts of developing and adult brain. Like other
members of receptor tyrosine kinase family, trk A
receptors are activated by ligand- induced dimerization
and autophosphorylation, which triggers the cellular

20   responses through the activation of the ras -MAP-kinase
pathway. Trk B and C, (but not trk A) are alternatively
spliced into two different types of receptor isoforms:
the full-length, tyrosine kinase (TK) domain-containing
form TK(+) and the truncated form TK(-). These isoforms

25   are identical in their extracellular and transmembrane
domains, but in place of the intracellular TK domain,
TK(-) forms only contain short unique intracellular tail
regions. Both receptor variants bind neurotrophins, but
only TK(+) can activate intracellular signal

30   transduction.

         For example, for the Trk A receptor, an antagonist
peptide may have the transmembrane domain amino acid
sequence AVFACLFLSTLLLVI (Sequence ID NO:89) or may be an
effective fragment or analogue thereof.

41

Antagonist peptides based on the amino acid sequence of the transmembrane domain of the trkA receptor provide therapeutic agents which can be used to reduce or inhibit nerve growth factor activity.

3.   Ion Channel and Channel Protein Antagonists

A number of integral membrane proteins, including the energy-dependent transporter pumps, form ion channels or ion channel receptors or are channel proteins.

(a) Bacterial Energy-dependent Transporter Antagonists

In accordance with a further embodiment of the invention, bacterial energy-dependent transporter antagonist peptides and a method for regulating or inhibiting the activity of the selected receptor are provided.

The integrity of bacterial membranes is maintained by a variety of membrane proteins, including bacterial ATPase transporter. Disrupting the function of the critical membrane protein may lead to loss of bacterial cell viability. The energy derived from metabolic processes in bacteria is used to generate ionic gradients across the cytoplasmic membrane. The ion-translocating enzyme, F_1F_0 ATPase, synthesizes ATP using a proton gradient and is the enzyme responsible for oxidative phosphorylation. The energy of the proton gradient drives ATP synthesis, catalyzed by the F_1F_0 ATPase. The *E. coli unc* operon, which codes for the ATPase, contains nine genes coding for the F_0 and F_1 domains of the enzyme. The F_0 portion is membrane-intrinsic and has three sub-units, a, b and c.

The amino acid sequence of the Gram negative Fo c subunit of the *E. coli* ATPase F_1F_0 is shown in Kanazawa et al. (1981) Biochemical and Biophysical Research Communications v. 103, pp. 613-620.

42

As an example of antagonist peptides for a
bacterial energy-dependent transporter, an antagonist
peptide for the E. coli F_1F_0 ATPase may have the Fo b sub-
unit transmembrane sequence MAAAVMMGLAAIGAAIGIGILGG
5   (Sequence ID NO:90) or the Fo c sub-unit TM sequence
NATILGQAIAFVLFVLFCM (Sequence ID NO:91) or may be an
effective fragment or analogue of one of these sequences.
The inventors have shown that peptide
GQAIAFVLFVL (Sequence ID NO:92), based on the amino acid
10   sequence of the TM domain of the Gram negative ATPase Fo
b subunit, and peptide LAAIGAAIGIGIL (Sequence ID NO:93),
based on the Fo c subunit, used alone or in combination,
could prevent the growth of *E. coli*, as described in
Example 9.
15   Antagonist peptides based on the amino acid sequence
of a TM domain of the Gram negative ATPase Fo b subunit
or Fo c subunit, provide therapeutic agents which can be
used as anti-bacterials.

(b)   Mammalian Energy-dependent Transporters

20   In accordance with a further embodiment of the
invention, mammalian energy-dependent transporter
peptides and a method for regulating or inhibiting the
activity of the selected transporters are provided.
P-glycoprotein or MDR1 protein, is an example of a
25   mammalian energy-dependent transporter. It is an energy-
-dependent efflux pump responsible for drug efflux and
decreased drug accumulation in multi-drug resistant (MDR)
cells.
The activation of the mdr1 gene which encodes the
30   protein can occur under various types of stimulation,
including under the effect of anti-cancer drugs.
P-glycoprotein is an ATPase transporter which is
believed to extrude xenobiotics from the plasma membrane
rather than from the cytoplasm. Although potential sites

43

of interaction of P-glycoprotein with its various ligands have been identified, especially at the level of putative transmembrane domains, the exact mechanism for drug pumping has never been elucidated. It is desirable

5   to have therapeutic agents which are able to reverse the multi-drug resistant state but are devoid of any pharmacological properties other than interaction with P-glycoprotein. Antagonists of P-glycoprotein would be an important adjunct to treatment of cancer with

10   chemotherapeutic agents.

As an example of antagonist peptides for the mammalian energy-dependent transporters, an antagonist peptide for P-glycoprotein may be selected from the relevant TM domain amino acid sequences shown in Table 4

15   or may be an effective fragment or analogue of any of these sequences.

Antagonist peptides based on the amino acid sequence of a TM domain of P-glycoprotein provide therapeutic agents for combatting multidrug resistance in

20   tumour cells, rendering them more susceptible to chemotherapeutic agents.

(c)   Ion Channel Antagonists

In accordance with a further embodiment of the invention, ion channel antagonist peptides and a method

25   for regulating or inhibiting the activity of a selected ion channel antagonist are provided.

An example of an ion channel is the γ-aminobutyric acid (GABA)-A receptor-chloride ion channel complex, which belongs to the ligand-gated receptor superfamily,

30   which also includes the 5HT3 serotonin receptor, the nicotinic acetylcholine receptor and the metabotropic glutamate receptor.

The GABA-A receptor-chloride ion channel is believed to be a complex of five membrane-spanning protein

44

subunits forming a heterooligomer. The subunits belong
to α, β, γ, δ or ρ class. Each subunit has an N-terminus,
four putative hydrophobic membrane-spanning domains and a
C-terminus, linked by extracellular and intracellular
5   loops (Schofield et al., (1987); Bernard, E.A., 1995).

      For example, an antagonist peptide for the GABA-A
receptor may be selected from the following transmembrane
amino acid sequences of the human α1-subunit:
     TM1 YFVIQTYLPCIMTVILSQVSFW (Sequence ID NO:33);
10   TM2 VPARTVFGVTTVLTMTTLSISA (Sequence ID NO:34);
     TM3 MDWFIAVCYAFVFSALIEFATV (Sequence ID NO:35);
     TM4 LSRIAFPLLFGIFNLVYWATYL (Sequence ID NO:36)

      GABA is the principal inhibitory neurotransmitter in
the vertebrate brain which mediates its actions (neuronal
15   inhibition) by binding to the integral membrane protein,
the GABA-A receptor. GABA-A receptors form a fast-acting
ligand-gated chloride ion-selective channel, that upon
activation by agonist, results in the hyperpolarization
of the neuron.
20   GABA-A receptor channels mediate the major
inhibitory synaptic events in the brain and are involved
in the regulation of anxiety, vigilance, memory,
epileptogenic activity and muscle tension. GABA-A
receptor subtypes have been identified in hippocampus
25   (Pyramidal and interneurons), olfactory bulbs (Mitral and
Granule cells), thalamus (relay neurons and Reticular
nucleus), and in the cerebellum (Purkinje and Granule
cells).
      A number of drugs which have their effect on the
30   brain act by binding to the GABA agonist site or receptor
channel; these include benzodiazepines which are
anxiolytic, barbiturates which are anti-convulsant, b-
carbolines which are anxiogenic and picrotoxin which has
convulsant effects. GABA antagonist peptides as described

herein may be used as therapeutics in similar disorders.

4. TRANSPORTER ANTAGONISTS

The family of transporter proteins are glycoproteins
5   with twelve putative membrane-spanning domains which
mediate sodium- and chloride-dependent re-uptake of
neurotransmitter. The neurotransmitter transporter
proteins provide a re-uptake mechanism for
neurotransmitters, thereby inactivating released
10 transmitter. This is the most important mechanism for
terminating synaptic transmission of endogenous ligands
such as catecholamines.

For example, for the dopamine transporter, an
antagonist peptide may be selected from the following
15 transmembrane amino acid sequences or may be an effective
fragment or analogue of any of these sequences:

    T1: FLLSVIGFAVDLANVWRFPYL (Sequence ID NO:37);
    T2: GAFLVPYLLMVIAGMPLFYM (Sequence ID NO:38);
    T3: GVGFTVILISLYVGFFYNVII (Sequence ID NO:39);
20   T4: WQLTACLVLVIVLLYFSLW (Sequence ID NO:40);
    T5: VVWITZTMPYVVLTALLL (Sequence ID NO:41);
    T6: VCFSLGVGFGVLIAFSSY (Sequence ID NO:42);
    T7: IVTTSINSLTSFSSGFVVFSFL (Sequence ID NO:43);
    T8:LPLSSAWAVVFFIMLLTGLI (Sequence ID NO:44);
25   T9: LFTLFIVLATFLLSLFCVT (Sequence ID NO:45);
    T10: GTSILFGVLIEAIGVAWFYGV (Sequence ID NO:46);
    T11: LCWKLVSPCFLLFVVVVSIV (Sequence ID NO:47);
    T12: LGWVIATSSMAMVPIYAAY (Sequence ID NO:48).

The distribution of transporters is consistent with
30 the distribution of neurotransmitters, suggesting that
transporters might be expressed specifically for the
neurotransmitter system. Transporter localization is
chiefly in the presynaptic neuronal membrane.

There are also high affinity transporter proteins

46

for norepinephrine, glutamate, aspartate, GABA, glycine, taurine, proline, adenosine and serotonin 5-HTT.

Abnormalities of the transporter proteins have been linked to several neuropsychiatric disorders (Uhl et al.,
5   (1994), J. Exp. Biol. v. 196, pp. 229-236).

The dopamine transporter and other monoamine transporters are the target of major classes of antidepressant and psychostimulant drugs. The dopamine transporter is also targeted by drugs of abuse such as
10   cocaine and amphetamine.

The antagonist peptides of the invention provide new, specific therapeutic agents useful in these dopamine transporter-related disorders as antidepressants and for the relief of drug craving and dependence.

15   The inventors have shown that peptide ALGWIIATS (Sequence ID NO:81), a fragment of the TM XII domain of the dopamine transporter, inhibited the cocaine-induced release of dopamine in caudate nucleus and nucleus accumbens of the live rat, as described in Example 10.
20

5.   IMMUNE RECEPTOR SUPERFAMILY

The CNS, vascular and immune systems share highly conserved specific, cell surface antigen receptors or immune receptors necessary for intercellular recognition.
25   Members of this superfamily of receptors have a large amino terminus, typically involved in antigen recognition, a single membrane-spanning domain and a carboxy tail. Some members of this superfamily, such as the FGF and VGF receptors, resemble the tyrosine kinase
30   receptors. Examples of cell surface antigen receptors include members of the immunoglobulin receptor superfamily such as CD4.

(a) Immunoglobulin Superfamily

In accordance with a further embodiment of the

invention, immunoglobulin superfamily antagonist peptides and a method for regulating or inhibiting the activity of the selected antagonist are provided.

CD4 is a T cell specific surface glycoprotein which
5 shows homology to members of the immunoglobulin superfamily. CD4 binds to nonpolymorphic regions of the major histocompatibility complex (MHC) class II molecule, thereby increasing the avidity of the T cell receptor for its ligand. CD4 interacts with at least two other T cell
10 surface molecules known to be involved in T cell activation, the T cell receptor (TCR) and CD3 complex. Extensive evidence suggests that CD4 is capable of functioning as a signal transduction molecule important for the activation pathway

15 CD4 receptor antagonists will provide new immunosuppressives for the treatment of CD4+ T-cell mediated autoimmune diseases and allograft transplant rejection. The CD4 receptor has also been identified as a necessary major coreceptor for HIV entry into cells.

20 Antagonist peptides based on the amino acid sequence of the TM domain of the CD4 receptor, MALIVLGGVAGILLFIGLGIFF (Sequence ID NO:94), provide therapeutic agents useful for the treatment of autoimmune disease, the control of allograft rejection and the
25 prevention or reduction of HIV infection.

The inventors have shown that peptide LIVLGGVAGLLLF (Sequence ID NO:181)based on the amino acid sequence of the TM domain of the CD4 inhibited HIV infection of PBMC cells, as described in Example 11.

30 **(b) TNF/NGF superfamily**

Physiological cell death (apoptosis) occurs when a cell within an organism dies by a mechanism orchestrated by proteins encoded by the organism's genome. The purpose of this process is to kill unwanted cells;

apoptosis occurs in three situations, namely, during development and homeostasis, as a defence mechanism and in aging.

Apoptosis inhibitors may be useful in treating
5   ischemic conditions such as heart attacks, strokes or reperfusion injury, by blocking the apoptotic response of cells subjected to sublethal amounts of anoxia. They may also be useful in allograft rejection and in rheumatoid arthritis or other autoimmune disorders.

10   The Tumor Necrosis Factor receptors, TNFR1 and TNFR2, belong to the TNF receptor superfamily which binds TNF-α as a mediator of apoptosis.

For example, for the TNFr1 and TNFr2 receptor, an antagonist peptide may have the TM domain amino acid
15   sequence VLLPLVIFFGLCLLSLLFIGLMY (Sequence ID NO:95) or ALPVGLIVGTALGLLIIGVVNCIMTOV (Sequence ID NO:96) respectively, or may be an effective fragment or analogue of such sequence.

Antagonist peptides based on the amino acid
20   sequence of the TM domain of TNFr1 or TNRr2, provide therapeutic agents which can reduce or inhibit apoptosis.

(c) C type lectin superfamily

CD94 is a type II membrane glycoprotein, and is a member of the C-type lectin superfamily. CD94 receptors
25   have been implicated in the regulation of Natural Killer (NK) cell function. An unexpected feature of CD94 is the essential absence of a cytoplasmic domain, implying that association with other receptors may be necessary for the function of this molecule.

30   **(d) Cytokine receptors**

CD95 is a member of the cytokine receptor superfamily. CD95 is a mediator of apoptosis and binds to the cytokine ligand FASL.

For example, for the CD95 receptor, an antagonist

49

peptide may have the transmembrane domain amino acid
sequence LGWLCLLLLPIPLIVWV (Sequence ID NO:97) or may be
an effective fragment or analogue of any of this
sequence.

5   **(e) EGF TM7 Superfamily**

CD97 is a seven-transmembrane receptor belonging to
the EGF TM7 superfamily. CD97 is expressed in leukocytes
and leukocytes strongly positive for CD97 are
concentrated at sites of inflammation, suggesting that
10   CD97 may play a signal transduction role associated with
the establishment or development of an inflammatory
process.

(f) TM4 superfamily

CD9 is an integral cell surface protein belonging to
15   the TM4 superfamily of receptors. CD9 is involved in the
aggregation of platelets and may participate also in
cell-cell interactions critical for correct orientation
and movement of maturing myeloid cells in bone marrow.

6.   ANTIGEN RECEPTOR ANTAGONISTS

20   A number of eukaryotic cell types have membrane-
associated antigen receptors which are integral membrane
proteins.

Exemplary of the group is the antigen receptor
occurring on many mammalian cells which recognises the T
25   cell antigen and provides the molecular basis for major
histocompatability complex (MHC) antigen recognition.
The receptor consists of two linked glyco-peptides, one
of which, the α-glycopeptide, consists of a transmembrane
domain and a cytoplasmic domain.

30   The amino acid sequence of the human T cell antigen
receptor α chain is disclosed in Yoshikai et al. (1985)
and the TM domain has the amino acid sequence:

DTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS (Sequence ID
NO:49). This sequence or an effective fragment or

analogue thereof provides an antagonist which will
interfere with the function of the T cell antigen
receptor. Such an antagonist provides a therapeutic agent
useful for control of autoimmune diseases or graft-

5   versus-host reaction.

EXAMPLES

The examples are described for the purposes of
illustration and are not intended to limit the scope of

10   the invention.

Methods of molecular genetics, protein and peptide
biochemistry and immunology referred to but not
explicitly described in this disclosure and examples are
reported in the scientific literature and are well known

15   to those skilled in the art.

Materials:

Animals Male Wistar rats (Charles River Breeding
Laboratories, St. Constant, QC) weighing about 250-350 gm
were utilized. Upon arrival, rats were housed in the

20   animal facility for acclimatisation for 1 week.

Peptides:

Peptides were synthesized using standard solid state
methodology by commercial suppliers. Peptides were stored
dessicated under refrigeration. Peptides may be

25   synthesised with a free carboxylic acid or a C terminal
amide, the amide form being preferred for its improved
stability. Most of the peptides described herein were
prepared in amide form. Typically for assessment of
receptor antagonism, peptides were prepared at a stock

30   concentration of 5 mg peptide per 1 ml of peptide buffer.
5 mg of peptides were dissolved in 100 ml DMSO, then
diluted to a volume of 1 ml with buffer (100 mM NaCl, 10
mM Tris-HCl, 2 mM EDTA), unless indicated otherwise.

The following listed peptides are examples of TM

51

domain peptides prepared to provide antagonists of the
indicated receptors:

1. Peptide Antagonists of G protein-coupled Receptors

Human dopamine D2 receptor: D2-TM I:

5 YATLLTLLIAVIVFGNVLVC; D2-TM II: VSLAVADLLVATLVMPWVVY; D2-
TM III: TLDVMMCTASILNLCAISID; D2-TM IV:
RVTVMISIVWVLSFTISCPL; D2-TM V: PAFVVYSSIVSFYVPFIVTL; D2-
TM VI: LAIVLGVFIICWLPFFITHI; D2-TM VII:
LYSAFTWLGYVNSAVNPIIY; D2-TM VII: TWLGYVNSA

10   Rat α1A adrenergic receptor: α1A-AR TM VII:

VFKVIFWLGYFNS; α1A-AR TM VII: VFKVIFWLGYFNSCVN;

        Rat β1 adrenergic receptor: β1-AR TM VII: GYANSAFNP;

β1-AR TM VII: FFNWLGYANSAFNP;

        Human β2 adrenergic receptor: β2-AR TM I: LIVVGNVLVI

15 (Sequence ID NO:98);

        Human CCR5 receptor: CCR5-TM 1: LYSLVFIFGFVGN; CCR5-
TM 7: MQVTETLGMT (Sequence ID NO:99);

        Human CxCR4 receptor: CXCR4 TM-1: PTIYSIIFLTGIV
(Sequence ID NO:100);

20   Human serotonin receptors: S1A-TM VII: PALLGAIIN
(Sequence ID NO:101); S1B-TM VII: FHLAIFDFFTWLG (Sequence
ID NO:102); S1B-TM VII: FHLAIFDFFTWLGYLNSLIN (Sequence ID
NO:51); S1D-TM I: QALKISLAVVLSV (Sequence ID NO:103);

        Human mu-opioid receptor: MOR-TM VII: IPETTFQTVSWH

25 (Sequence ID NO:104);

        Human angiotensin I receptor: AT1-TM VII:
DTAMPITISIAY (Sequence ID NO:105); AT1-TM VII:
VDTAMPITICIAYFNN (Sequence ID NO:52);

        Human vasopressin 2 receptor: V2-TM VII:

30 LMLLASLNSCTNPWIY;

        Human NPY5 receptor: NPY5-TM I: YFLIGLYTFVSL
(Sequence ID NO:106);   '

        Human melanocyte stimulating hormone receptor: MSH-

52

TM 1: ISDGLFLSLGLVS (Sequence ID NO:107).

2. **Peptide Antagonists Of Tyrosine Kinase Receptors**

Human EGF-erb1 receptor: EGFR1-TM: VGALLLLLVVALG (Sequence ID NO:108);

5   Human EGF-erb3 receptor: EGFR3-TM: LTVIAGLVVIFMMLGG (Sequence ID NO:109); EGFR3-TM: LTVIAGLVVIF;

Human Fibroblast Growth Factor receptor: FGFr1-TM: EIIIYCTGAFLIS (Sequence ID NO:110); FGFr2-TM: VVTVILCRMKNTT (Sequence ID NO:111);

10   Human Vascular Endothelial Growth Factor receptor: VEGFr1-TM: SYSFQVARGMEFL (Sequence ID NO:118);

Human TrkA receptor: TrkA-TM: FASLFLSTLLLVI (Sequence ID NO:113);

3. **Peptide Antagonists of Ion Channels**

15   E. Coli ATPase Fo c subunit: GQAIAFVLFVL

E. Coli ATPase Fo b subunit: LAAIGAAIGIGILG

P-glycoprotein: VGTLAAIIHGAGL (Sequence ID NO:114)

GABA-A: GIFNLVYW (Sequence ID NO:115)

4. **Peptide Antagonists of Transporters**

20   Human dopamine transporter: DAT-TM XII: ALGWIIATS; DAT-TM XII: PDWANALGWVIIATS (Sequence ID NO:116);

5. **Peptide Antagonists of Immunoreceptors**

Human CD4 receptor: LIVLGGVAGLLLF

6. **Peptide Antagonists of TNF receptors**

25   Human tumor necrosis factor receptors: TNFR1-TM: TVLLPLVIFFGLSL (Sequence ID NO:117); TNFR2-TM: PVGLIVGVTALGL (Sequence ID NO:118)

7. **Peptide Antagonists of Cytokine receptors**

CD95-TM: WLCLLLLPIPLIVW (Sequence ID NO:119)

30

Example 1 - Inhibition of binding to dopamine D2 receptor

Construction of Recombinant D2 receptor encoding
baculovirus: Recombinant baculovirus encoding the human D2L receptor was constructed using standard recombinant

53

techniques. Briefly, a cDNA clone encoding the long form
of the human D2 receptor (D2L) was extracted from the
pZem 3 vector with DraIII and KpnI. The resulting
fragment was blunt ended and isolated by electrophoresis
5   on soft agarose. The transfer vector pJVETLZ New was
digested with NehI and blunt ended. The cDNA fragment
coding for the D2L receptor was inserted into this vector
by blunt-end ligation and the orientation verified by
sequencing.

10   Transfer of recombinant baculovirus encoding the D2L
receptor into the AcNPV genome was achieved by co-
transfection of plasmid and wild-type viral DNA in Sf9
cells using the calcium phosphate precipitation
procedure. Purification of recombinant virus was carried
15 out as described by Vialard et al., 1990, and stocks of
the purified recombinant viruses were amplified in Sf9
cells.

Construction of D2 receptor encoding pcDNA3 expression
vector: The pHD2$_s$-Zem plasmid containing the entire
20 coding sequence of the human D2$_s$ receptor was used as the
template in the polymerase chain reaction (PCR) for the
construction of pcDNA3 expression vectors encoding the
full-length D2 receptor and truncation mutants. The
D2/pcDNA3 expression vector was constructed as follows:
25 The oligonucleotides
(5'ACGCGGCCGCAGGCTGCTGTGCGGGCAGGCACGAG AGTCAGCAG
TGGAGGATCTT3' and 5'GCAAGCTTGCCACCCAGTCGGTCCACCGC3') were
used in the PCR reaction to generate a HindIII/NotI
fragment encoding the full-length D2 receptor which was
30 isolated by agarose gel electrophoresis and inserted into
pcDNA3 at HindIII and NotI sites.

Construction of DNA plasmid encoding TM VII peptide of
the D2 receptor: The D2-TM VII/pcDNA3 expression vector
was constructed as follows: The oligonucleotide encoding

54

an initiator ATG codon, aa of TM VII of the D2 receptor, a stop TAG codon, and a XbaI site was chemically synthesized (5'ATGACGTGGCTGGGCTATGTCAACAGCGCCTGATCT AGA3'). This was annealed to a complementary

5   oligonucleotide to produce double-stranded oligonucleotides which were digested with XbaI. The pcDNA3 vector was digested with HindIII and the ends filled with T4 DNA polymerase. The linearized pcDNA3 vector was digested with XbaI, and the double-stranded

10 oligonucleotide subcloned into the pcDNA3 vector by blunt and sticky-end ligation. The sequence and insertion of the synthetic oligonucleotides into the vector at the appropriate site and orientation was verified by sequencing from both ends. A single oligonucleotide

15 insert repeat was found.

    Sf9 Cell Culture: Sf9 cells were grown in monolayer or suspension culture essentially as described by Summers and Smith (1987) in supplemented Grace's insect media at 27 °C. Pluronic F-68, a cell protective agent, was added

20 to improve cell viability in suspension culture since Sf9 cells are very sensitive to mechanical shear. Cells at a density of $1-2 \times 10^6$/ml were infected with the recombinant virus at a multiplicity of infection of 2-5 and harvested at 24 or 48 h post-infection. Typically, viral

25 infections were performed with a final cell density of 2 $\times 10^6$ cells/ml. Cell viability at these times were ~90% (trypan blue-negative) as determined by trypan blue staining. To minimize variations in recombinant baculovirus infection efficiencies among batches of

30 cultures, the same recombinant virus stock was used in all experiments for a study.

    COS and CHO cell culture and DNA transfection: COS-7 monkey kidney cells (American Type Culture Collection) were maintained as monolayer cultures at 37 C in

55

Dulbecco's modified Eagle's medium supplemented with 10%
fetal bovine serum and Penicillin and Streptomycin. CHO
cells were cultured in Ham's F-12 media containing 10%
fetal bovine serum. COS and CHO cells were transiently
5   transfected with recombinant pcDNA3 expression vectors (8
µg) by calcium phosphate precipitation methodology as
described by the manufacturer (BRL, Life Technologies
Inc.). In receptor co-expression studies, D2/pcDNA3 (8
µg) was co-transfected with D2 TM-VII/pcDNA3 (8 µg) or
10   pcDNA vector (8 µg) into COS-7 cells as described above.
Preparation of Cell Membrane Fractions: The preparation
of membranes was done at 4°C. Cells were centrifuged at
100xg for 7 min. and pelleted. Cells were then washed
twice with PBS and centrifuged at 100xg for 7 min (X2)
15   and resuspended in 10 ml of buffer A: 5 mM Tris-HCl, 2 mM
EDTA buffer containing the protease inhibitors: 10mg/ml
benzamidine, 5 mg/ml leupeptin, and 5 mg/ml soybean
trypsin inhibitor (pH 7.4 at 4°C). The cell suspension
was then sonicated, two bursts at maximum setting for 15
20   seconds and homogenates were centrifuged at 100xg for 7
min. to pellet unbroken cells and nuclei, and supernatant
was collected. The resulting pellet was homogenized a
second time in 10 ml of buffer A, centrifuged as
described above and supernatant fractions saved. The
25   pooled S1 supernatant was centrifuged at high speed
(27,000 xg for 20 min), washed once with buffer A,
centrifuged again at high speed and resuspended in buffer
A, and stored at -80 C or resuspended in buffer B: 75 mM
Tris-HCl, 12.5 mM $MgCl_2$, 2 mM EDTA, pH 7.4 and assayed
30   immediately for adenylyl cyclase activity. Pelleted
membranes (P2 membranes) were resuspended in buffer A and
stored at -70° C or resuspended in the appropriate buffers
for immediate use in various assays.
Protein Determination: Protein content was determined by

56

the method of Bradford (BioRad). A standard protein
concentration curve was made with bovine serum albumin
(BSA). Protein concentration in the test sample was
determined from the standard curve which was a plot of
5   absorbance at 595 nm measured using a Hitachi model U-
2000 spectrophotometer against concentration.

Solubilization And Immunoprecipitation Of Receptors:
Membranes were prepared by sonication in buffer A as
described above. The pellet was resuspended and stirred
10 at 4°C for 2 h in 2 ml of freshly prepared solubilization
buffer consisting of 100 mM NaCl, 10 mM Tris-HCl pH 7.4,
2% digitonin, and 5 mM EDTA with protease inhibitors.
The homogenate was centrifuged at 27000xg for 20 min and
the solubilized fraction was washed and concentrated in
15 Centriprep 30 four times with 10 ml cold buffer C: 100 mM
NaCl, 10 mM Tris-HCl pH 7.4 with protease inhibitors.
The washed fraction was precleared with 1/20 normal
rabbit serum and protein A-Sepharose beads for 2 h on
ice. Solubilized receptors were immunoprecipitated with
20 the mouse monoclonal 9E10 antibody (D1 receptor) or
rabbit polyclonal (D2 receptor) at a 1/37 dilution in
buffer C for 2 h on ice, and agitated gently overnight at
4°C with 1/40 dilution of agarose fixed goat anti-primary
IgG. The immunoprecipitate was washed 6 times with 5
25 volumes cold buffer C for 20 min, solubilized in SDS
sample buffer, sonicated and electrophoresed on SDS-PAGE
as described above.

Soluble Receptor Binding: The amount of solubilized and
immunoprecipitated receptor was determined by radioligand
30 binding. D2 receptor density was estimated by incubating
in the presence of saturating concentrations (~2000 pM)
of the benzamide antagonist [^{3}H]YM-01951-2 _or_
butyrophenone antagonist [^{3}H]_spiperone_ for 2 h at 22°C in
a total volume of 1 ml binding buffer: 100 mM NaCl, 10

mM Tris-HCl, 0.05% digitonin, 2mM EDTA with protease
inhibitors, pH 7.4. Nonspecific binding was defined by
binding not displaced by 1 mM (+)butaclamol. Following
the incubation period, the binding preparation was loaded
5   onto a Sephadex G-50 column (Pharmacia) and ligand bound
receptor was separated from free ligand by elution. The
eluate was counted in a scintillation counter for
determination of the amount (pM) of receptor.
SDS-PAGE Electrophoresis: Sodium dodecyl sulphate 10-12%
10 polyacrylamide gel electrophoresis (SDS-PAGE) was
performed as described by Laemmli, 1970.
Immunoprecipitated membranes were solubilized in SDS
sample buffer consisting of 50 mM Tris-HCl pH 6.5, 10%
SDS, 10% glycerol, and 0.003% bromophenol blue with or
15 without 10% 2-mercaptoethanol. Molecular mass (Da) of
receptors was determined graphically by plotting the log
molecular weight of known protein standards versus the RF
(relative migration) of these proteins. The apparent
molecular mass of proteins was estimated by determining
20 the RF (from the centre of the band) and interpolating
this value onto the standard curve.
Immunoblot Analysis: Membranes from cells infected with
recombinant virus or with wild-type baculovirus were
prepared and subjected to SDS-PAGE electrophoresis as
25 described above and blotted on to nitrocellulose. The
blots were washed in TBS for 10 min, blocked with 3% skim
milk powder in TBS buffer for 30 min, washed for 10 min
and incubated for 1 h at 22°C with the mouse monoclonal
antibody (9E10) directed against the c-myc epitope of the
30 c-myc-D1 receptor, or with the polyclonal antibody
against a 120 amino acid sequence (nt 661-1020) in the
third intracellular loop of the human D2 receptor.
Primary antibodies were diluted 1/1000 in TBS containing
1% skim milk powder. Blots were then treated with 0.05%

58

Tween 20 in TBS for 30 min and binding of the primary
antibody was detected after incubation for 1 h at 22 C
with goat anti-mouse or goat anti-rabbit IgG alkaline
phosphatase conjugate diluted 1/1000 in TBS containing 1%
5   skim milk powder. Blots were then rinsed in 150 mM NaCl,
50 mM Tris-HCl pH 7.5 before developing with BCIP/NBT (5-
bromo-4-chloro-3-indolyl phosphate/nitroblue terazolium)
substrate.

Preparation of human caudate tissue: Human caudate
10 tissue was obtained from the Canadian Brain Tissue Bank
and cell membranes were isolated and receptors
solubilised and immunoprecipitated as described above.

Radioligand binding studies on P2 membranes: P2 membranes
were prepared as described above. Saturation binding
15 experiments were performed with ~25 µg P2 membrane
protein with increasing concentrations of [^{3}H]spiperone
(10-2000 pM, final concentration) in duplicate
determinations in 50 mM Tris-HCl, 5 mM EDTA, 1.5 mM CaCl$_2$,
5 mM MgCl$_2$, 5 mM KCl, 120 mM NaCl buffer with protease
20 inhibitors in 1 ml final volume. Competition experiments
were done by preincubating P2 membranes with various
amounts of peptide for 1/2 h followed by addition of
[^{3}H]spiperone at a concentration equivalent to its K_D and
binding buffer to a volume of 150 ml.   Nonspecific
25 binding was defined as binding that was not displaced by
1 µM (+)-butaclamol. Bound ligand was isolated by rapid
filtration and washing through a Brandel 48-well cell
harvester using Whatman GF/C filters. Binding data were
analysed by nonlinear least-squares regression using the
30 computer-fitting program INPLOT version 3.0 GraphPad (San
Diego).

GTP-γS binding: Receptor function was assessed by
receptor-mediated, agonist-stimulated [^{35}S]GTPγS binding.
The assay mix contained 0.05 ml of crude membranes, 40

ml [^{35}S]GTPγS binding buffer (50 mM Tris-HCl, 5 mM MgCl$_2$,
100 mM NaCl, 20 mM GDP, ~280 pM [^{35}S]GTPγS),40 ml peptide
antagonist (5 mg in 1 ml 10% DMSO buffer). This was
preincubated for 15 min at 37°C and 20 ml agonist (1 mM,
5   final concentration) added. Bound [^{35}S]GTPγS was
separated from free by filter filtration.
In Vitro Receptor disruption: 3 pmol of isolated and
solubilised receptors, as determined by soluble binding
assay, were prepared in buffer A (100 mM NaCl, 10 mM
10 Tris-HCl pH 7.4, mM EDTA and 0.5% digitonin with 5 mg/ml
leupeptin, 10 mg/ml benzamidine and 5 mg/ml soybean
trypsin inhibitor), and incubated with 1.6 g/l (final
concentration) of peptide (unless otherwise indicated).
In these experiments, 5 mg of peptide were freshly
15 dissolved in 100 ml DMSO and 100 ml Digitonin (5% w/v
solution) and 800 ml buffer A. SDS buffer (50 mM Tris-
HCl, pH 6.5/12% SDS/10% 2-mercaptoethanol/10% (vol/vol)
glycerol/0.003% bromophenol blue) was added to the
samples to make a total assay volume of 30 ml, and
20 incubated at 37°C for 30 min prior to SDS-PAGE and
immunoblot analysis.

Receptor temperature stability studies were
performed with 1.5 pmol of immunoprecipitated D2
receptors. Receptors were prepared in buffer A and
25 incubated at 23, 37, 65, and 90°C for 30 min with SDS
buffer at a final volume of 30 ml, and subjected to SDS-
PAGE and immunoblot analysis.

Receptor pH-stability experiments were performed
with 1.5 pmol of immunoprecipitated D2 receptors prepared
30 in buffer A. Receptors were treated with H$_2$O, or 0.1 N
tartaric acid (final concentration), or 0.1 N HCL (final
concentration), or 0.1% glacial acetic acid (final
concentration). Samples were then incubated at 37°C for

30 min with SDS buffer at a final volume of 30 ml, and
subjected to SDS-PAGE and immunoblot analysis.

B: Peptide-induced specific disruption of receptors: D2
receptors immunoprecipitated from membranes prepared from
5 D2/Sf9 cells exist in the presence of sodium dodecyl
sulphate (SDS) and reducing agent (2-mercaptoethanol) as
~44 kDa species at the predicted size of the D2 receptor,
and as ~90 kDa species at approximately twice the
molecular mass interpreted to be D2 dimers (Fig. 3A, lane
10 1). The dissociation of the D2 dimer to monomer was
accomplished in a dose-dependent manner upon addition of
the hydrophobic peptide LAIVLGVFIICWLPFFITHI, aa 375-394
of the D2 receptor, within the TM VI domain(Fig. 3B) or
the peptide LYSAFTWLGYVNSAVNPIIY, aa 407-426 of the D2
15 receptor, within the TM VII domain(Fig. 4B). Both of
these peptides, containing no strongly polar residues,
had similar ability to dissociate D2 dimers
immunoprecipitated from a human caudate preparation as
well (Fig. 3C). A small increase in the molecular mass
20 of receptor monomer in samples coincubated with peptide
was noted, which may be attributed to the formation of a
peptide-D2 receptor heterodimer.

     Peptide antagonists receptor and site-specific since
no disruption of D2 dimers was observed under identical
25 experimental conditions using the hydrophilic peptide
CTHPEDMKLCTVIMKSNGSF (Sequence ID NO:62), aa 244-263 of
the D2 receptor C IIIA domain and peptide
LSSTSPPERTRYSPIPPSHH (Sequence ID NO:63), aa 284-303) of
the D2 receptor C IIIB domain or third cytoplasmic loop
30 of the D2 receptor, or a hydrophobic peptide (aa 276-296)
corresponding to a portion of the TM-VI region of the β2-
adrenergic receptor (β2-AR), or two peptides derived from
the carboxyl tail of the D1 receptor (aa 369-383 and aa
416-431) (Fig. 3D). In addition, no dissociation of

61

immunoprecipitated human dopamine D1 and serotonin 5-HT1B
receptor dimers was observed with the D2-TM VII peptide
fragment (Fig. 3E). These results indicate that
synthetic peptides derived from hydrophobic putative

5   transmembrane domains of receptor proteins can interact
specifically to disrupt receptors as noncompetitive
antagonists.

C: Physicochemical disruption of D2 receptor dimers:
Consistent with the model that D2 receptors exist as

10   dimers, D2 dimers dissociate as a function of increasing
temperature (Figure 3F) or in the presence of acid
(approximate pH 3.0) (Figure 3G).

D: TM peptide disruption of D2 receptor ligand binding:
Peptides derived from the TM 5 (PAFVVYSSIVSFYVPFIVTL) and

15   TM 7 (TWLGYVNSA) domains of the D2 receptor inhibited
[^{3}H]-spiperone binding to P2 membranes prepared from D2
receptor-expressing Sf9 cells in a dose-dependent manner
(Fig. 4). The inhibition was receptor subtype-specific,
since TM peptides from the vasopressin V2 receptor-TM7

20   (LMLLASLNSCTNPWIY), TM-12 of the dopamine transporter
(ALGWIIATS) and TM-1 of the GABA receptor A subunit
(GIFNLVYW) had a much smaller effect on D2 receptor
binding (Figure 4).

A peptide derived from the TM-7 domain of the D2

25   receptor (TWLGYVNSA) inhibited [^{3}H]-quinpirole binding to
P2 membranes prepared from D2 receptor expressing Sf9
cells in a concentration-dependent manner (Fig. 5, right
panel). A similar result was obtained by competition of
quinpirole binding with the prototypic D2 receptor

30   antagonist spiperone (Figure 5, left panel). These data
indicate *in vitro* TM peptide inhibition of D2 receptors
in accordance with the invention.

*E: TM peptide inhibition of D2 receptor stimulated GTP-γS
binding:* In control P2 membranes, dopamine mediated a

62

dose-dependent stimulation of [^{35}S]-GTP-γS binding
(Figure 6, left panel). Pretreatment of P2 membranes with
a peptide derived from the TM-7 of the D2 receptor
(TWLGYVNSA) completely inhibited the dopamine-induced
5   activation in a dose-dependent manner (Fig. 6, right
panel). The inhibition was specific to D2-derived
peptides, since the peptide derived from the TM domain of
the GABA-A receptor subunit (GIFNLVYW) had no effect on
dopamine activation at equivalent peptide concentrations,
10   (Figure 7, right panel). The inhibition of D2 receptor
stimulated GTP-γS binding by the D2 TM-7 peptide (Figure
7, right panel) was similar in response to the
prototypical D2 receptor antagonist, spiperone (Fig. 7,
left panel). These data indicate in vitro TM peptide
15   disruption of D2 receptors.

*F: Co-expression of the D2-TM 7 peptide with the D2
receptor in living cells results in loss of D2 receptor
binding:* Co-expression of the D2 TM-7 peptide TWLGYVNSA
with the full-length D2 receptor in COS-7 cells resulted
20   in a 64% loss of saturable spiperone binding (Figure 8,
open circles) relative to binding by cells expressing the
D2 receptor alone (Fig. 8, solid circles), with little
change in spiperone affinity. These data indicate in
vivo inhibition of D2 receptors by gene-delivered TM
25   peptide.

Example 2 - Inhibition of dopamine D2 receptor function
in vitro
Methods

Adenylyl Cyclase Activity: Adenylyl cyclase assays
30   were conducted essentially as described (Salomon et al.,
1974). The assay mix contained 0.02 ml of membrane
suspension (10-25 µg of protein), 0.012 mM ATP, 0.1 mM
cAMP, 0.053 mM GTP, 2.7 mM phosphoenolpyruvate, 0.2 units
of pyruvate kinase, 1 unit of myokinase and 0.13 µCi of

63

[^{32}P]ATP in a final volume of 0.05 ml. Enzyme activities
were determined in duplicate or triplicate assay tubes
containing 10^{-3} - 10^{-9} M dopamine or 100 µM forskolin or 10
mM sodium fluoride and incubated at 37° C for 30 mins.

5 For inhibitory receptors such as the D2L receptor,
adenylyl cyclase activity mix contained 100 µM forskolin.
Inhibition of adenylyl cyclase assays was determine
following incubation at 27° C for 20 mins. Reactions were
stopped by the addition of 1 ml of an ice-cold solution

10 containing 0.4 mM ATP, 0.3 mM cAMP and [^{3}H]cAMP (25000
cpm). Antagonist inhibition of dopamine stimulated
cyclase was performed with increasing concentrations of
peptide in the presence of 10 µM dopamine. cAMP was
isolated by sequential column chromatography using Dowex

15 cation exchange resin and aluminum oxide. Data were
analysed by computer fitted nonlinear least-squares
regression.

Co-expression of the D2-TM 7 peptide with the D2 receptor
in living cells results in loss of receptor-inhibited

20 *adenylyl cyclase activity:* In membranes from D2
receptor-expressing CHO cells, dopamine mediated a 13%
inhibition of adenylyl cyclase activity, indicated by a
decreased production of cyclic AMP (Figure 9, open bar).
Dopamine inhibition of adenylyl cyclase activity was

25 descreased to 7% in membranes from cells co-expressing
the D2 TM-7 peptide with full-length D2 receptors (Fig.
9, shaded bar). These data indicate *in vivo* inhibition of
the D2 receptor by gene-delivered TM peptide.

Example 3- Inhibition of dopamine D2 receptor function *in*

30 *vivo*

A: **METHODS**

Stereotaxic surgery: Male Wistar rats (~300-350 g) were
anaesthetized with ketamine (66 mg/kg i.p.), acepromazine
(3 mg/kg i.p.) and pentobarbital (22 mg/kg i.p.) for

64

chronic stereotaxic implantation. A unilateral stainless
steel guide cannula (G22) was placed into the centre of
the left caudate putamen (Ant. +1.5, Lat. -2.2, Vert. -
5.0, Paxinos and Watson, 1982) to allow drug or vehicle
5   injection. Alternatively, bilateral stainless steel
guide cannulas (G22) were stereotaxically placed into the
centre of left and right caudate putamens for both drug
and vehicle injections respectively. The guide cannula
was kept patent by stylets (Plastic Products Company,
10 Roanoke, VA) terminating 0.5 mm below the guide tips
which were located 2 mm above the point of injection.
The rats were allowed a week postoperative recovery
before experimental use.
Intracerebral injection technique. The stylets were
15 withdrawn and injections (drug or vehicle) made into
conscious rats using a 28 gauge internal cannula
connected by PE-50 polyethylene tubing to a gastight
Hamilton syringe. The stylets were then replaced. For
unilateral operated animals, a total of 2-3 ml drug in
20 vehicle or vehicle alone was injected into the left
striatum, followed 15 min after by a subcutaneous
injection of 0.25 mg/kg apomorphine. Rats with bilateral
cannulas were administered drug into the left striatum
and vehicle into the right striatum, followed 15 min
25 after by a subcutaneous injection of 0.25 mg/kg
apomorphine.
Behavioural scoring. The intensity of the behavioral
response was assessed every 2-5 min post-injection.
Asymmetry (ipsilateral to the side of peptide or vehicle
30 injections) was scored on the 0-3 system, 15 min after
subcutaneous challenge with apomorphine (0.25 mg/kg).
Animals showing an ability to move in right and left
directions were not categorized as circling. However, an
ability to circle in one direction (asymmetric body

65

posture) was scored on a 0-3 response according to
observations in the open field and to the lifting of the
tail. The criteria which met the 0-3 scores were:
0=no asymmetry, response of animals the same as untreated

5   rats.
1=a distinct tendency for animals to move in one
direction when handled but still capable of movement in
either direction.
2=spontaneous movements in one direction, a twisting of

10   the body in this direction, exaggerated when handled,
with inability to move in opposite direction.
3=a marked and intense twisting of the body, active
circling movements when disturbed, the animal being
unable to move in the opposite direction.

15   **B: INHIBITION OF D2 RECEPTOR ACTIVITY**
     The effect of D2 receptor transmembrane peptides on
D2 receptor activity was studied using the accepted
animal model described by Costall et al. (1983), for
screening dopamine receptor antagonists. Effect of

20   unilateral intrastriatal injection of receptor peptides
on motor behavior. Following unilateral injection of
peptides (D2-TM VII or β2-AR-TM VI) or vehicle into the
left striatum, animals were observed for 1 h. All
treatments failed to induce circling responses.

25   Circling following unilateral intrastriatal
injection of D2-TM VII peptide and challenge with
subcutaneous apomorphine. Subcutaneous challenge with
apomorphine 15 min post unilateral intrastriatal
administration of the D2-TM VII, but not β adrenergic

30   peptide or vehicle, revealed an ipsilateral asymmetric
body posturing in rats achieving a behavioral response
score of 3 (Fig. 10). Similar ipsilateral asymmetric
body posturing in rats was observed in bilaterally
cannulated rats following intrastriatal administration of

66

D2-TM VII and vehicle into left and right striatum
respectively (Fig. 11). The results indicate that D2-TM
VII peptide acts pharmacologically as a classical D2
receptor antagonist.

5   Example 4 - Inhibition of binding to β adrenergic
receptor

A: METHODS

*Recombinant β2-adrenergic receptor encoding
baculoviruses:* Recombinant baculovirus encoding the c-

10   myc epitope tagged b_2-adrenergic receptor was constructed
using standard recombinant techniques, as described
above. Recombinant baculovirus encoding a histidine-
tagged TM-7 domain of the $β_2$-adrenergic receptor was
constructed using the Bac-to-Bac system according to

15   manufacturers' instructions. Briefly a complementary
oligonucleotide encoding the TM-7 domain of the $β_2$-
adrenergic receptor was ligated and subcloned into the
multiple cloning site of the pFASTBAC His expression
vector by standard recombinant techniques. The

20   orientation of the cDNA was verified by sequencing.
Transfer of the pFASTBAC encoding the His-tagged TM-7 of
the β2-adrenergic receptor into the AcNPV genome and
purification of recombinant virus was carried out as
recommended by the manufacturer (BRL Life Technologies).

25   *Cell culture and preparation of membrane fractions and
solubilization of receptors:* Sf9 cell culture,
preparation of membrane fractions and solubilization of
receptors were as described in Example 1.

Ni-NTA purification of histidine-tagged proteins: Sf9

30   cells co-expressing histidine-tagged β2-AR Tm7 peptide
and full-length c-myc tagged β2-AR were disrupted under
native conditions. The cell lysate was passed by
gravity-flow over a Ni-NTA resin to purify histidine-

tagged proteins. Histidine-tagged proteins generated in
Sf9 cells were eluted from the resin according to the
BAC-to-BAC kit instructions (BRL, Life Technologies).
SDS-PAGE and Immunoblot Analysis: were carried out as in

5   Example 1. Immunoreactive histidine-tagged β_2-AR TM 7
peptide was revealed with a rabbit polyclonal antibody
raised against the 6XHIS sequence (Santa Cruz Biotech.
Inc.). Immunoreactive c-myc epitope-tagged β_2-AR was
detected with mouse monoclonal 9E10 antibody, raised

10   against a peptide corresponding to amino acids 408-439 of
the human c-myc protein (Santa Cruz Biotech. Inc.).
Soluble $\beta 2$-adrenergic receptor binding: $\beta2$-adrenergic
receptor binding was estimated by incubating solubilized
membranes from $\beta2$-adrenergic receptor expressing Sf9

15   cells (75 ml) in the presence of saturating
concentrations of ^{3}H-alprenolol (15 ml) for 2 hrs at 22 °C
in a total volume of 150 ml soluble binding buffer
(described above). Competition experiments were done by
preincubating soluble $\beta2$-adrenergic receptors with

20   peptide (40 ml of a 5 mg /ml peptide stock made in 10%
DMSO buffer) for 1/2 h followed by addition of
[^{3}H]alprenolol and binding buffer to a volume of 150 ml.
Non-specific binding was defined as binding not displaced
by 1 mM pindolol. Bound receptor was separated from free

25   ligand by elution from Sephadex G-50 columns and binding
activity determined by scintillation counting.

*B: Immunological detection of a histidine-tagged $\beta2$-TM 7
peptide - c-myc epitope tagged $\beta2$ receptor heterodimer*:
To ascertain that peptides based on TM domains of a

30   receptor interacted with the target receptor, a
histidine-tagged TM-7 peptide of the β_2-adrenergic
receptor was co-expressed with a full-length c-myc-

68

epitope tagged β_2-adrenergic receptor in Sf9 cells. A histidine-tagged $\beta2$-TM 7 peptide – c-myc epitope tagged β_2 receptor heterodimer should be detectable on immunoblots of Ni-NTA purified receptors. An antibody against the

5 His tag of the TM-7 peptide revealed on immunoblot a species at the expected molecular mass (~50 kDa) of a heterodimer (Figure 12, right panel). In the identical preparation, the same species was detected as an immunoblot with the 9E10 antibody, (Figure 12, left

10 panel), demonstrating interaction of the transmembrane-derived peptides with the full-length receptor. These data indicate *in vitro* TM peptide inhibition of adrenergic receptors.

C: Inhibition of β_1-adrenergic receptor binding by subtype

15 *selective peptides:* [^{3}H]-alprenolol binding to the β_2-adrenergic receptor was inhibited by a peptide derived from the TM-1 domain of the β_2-adrenergic receptor ($\beta2$-AR TM I: LLIVVGNVLVI) (Fig. 13A). Similar results were obtained for the prototypical β_2-adrenergic receptor

20 antagonist pindolol (Fig. 13B). A peptide derived from the TM-7 of the β_1-adrenergic receptor ($\beta1$-AR TM VII:GYANSAFNP), two peptides derived from the TM domain of the ATP-ase subunit (*E. Coli* ATPase Fo b subunit: GQAIAFVLFVL; *E. Coli* ATPase Fo c subunit:

25 LAAIGAAIGIGILG), and a peptide derived from the TM 1 domain of the CCR5 receptor (LYSLVFIFGFVGN) had a negligible effect on [^{3}H]-alprenolol binding (Fig. 13A). These data indicate highly specific inhibition of an adrenergic receptor by peptides derived from the

30 transmembrane domain of the receptor, but not by peptides derived from the transmembrane domain of the closely related $\beta1$ adrenergic receptor.

Example 5 - Inhibition of α adrenergic and β adrenergic

receptor activity _in vivo_

A: **METHODS**

Animals Male Wistar rats (Charles River Breeding
Laboratories, St. Constant, QC) weighing about 250-350 gm
were utilized. Upon arrival, rats were housed in the
animal facility for acclimatisation for 1 week.

Surgery Prior to the experiments, the rats were fasted
overnight but provided with water _ad libitum_. Under
halothane anesthesia, the left femoral or jugular vein
was exposed, cleaned, clamped and cannulated with
polyethylene tubing (Tygon; PE 10-20) for intravenous
injections of drugs. The right carotid artery was then
exposed adjacent to the trachea and cannulated for blood
pressure recording (PE 10-20 tubing). The cannulae were
tunneled subcutaneously to the midback of the animal
where they were brought out onto the skin surface and
capped with rubber injection ports. All catheters were
filled with a solution of heparin (10 units/ml) and were
flushed periodically with the same solution to prevent
clotting.

Cardiovascular measurements Rats were allowed to wake up
and recover for 3 hrs prior to cardiovascular
measurements. A transducer was connected to the carotid
arterial catheter, and blood pressure was recorded on a
polygraph. Animals were given atropine 1 mg/Kg
subcutaneously 2 to 3 hours before measurement of
adrenergic responses to antagonise cholinergic tone.

Measurement of adrenergic receptor responses All drugs
were injected intravenously (femoral or jugular vein) in
bolus volumes of 0.1 - 0.2 ml and flushed in with 0.2 ml
of saline. Blood pressure was recorded continuously by
polygraph.

B: **Inhibition of β1-adrenergic receptor activity**

The effect of adrenergic receptor antagonist

70

peptides was examined using an accepted animal model for
assessing cardiovascular drugs.

After a period of recording baseline cardiac
function, in an awake and freely-mobile rat, (480

5   beats/min, with systolic/diastolic blood pressure of
160/110 min Hg, as seen in Figure 14A), the rat was given
1 mg/Kg of the β1-adrenergic receptor agonist,
isoproterenol, by rapid IV bolus.

This produced a marked increase in spontaneous

10   cardiac activity, with a rise to 600 beats/min and an
accompanying reduction in blood pressure to 140/70
(Figure 14B).

After an interval to allow baseline parameters to be
reestablished, 100 ml of 5 mg/ml peptide FFNWLGYANSAFNP,

15   a fragment of the β1-adrenergic receptor TM VII peptide,
(β1-TM7) was administered intravenously.

As seen in Figure 14C, there was a marked reduction
in spontaneous cardiac activity to 240 beats/min with a
selective drop in diastolic blood pressure to give

20   160/60, indicative of β1-adrenergic receptor antagonism.

After baseline parameters were again reestablished,
a further 1 mg/Kg isoproterenol was administered. The
response to isoproterenol was attenuated, as seen in
Figure 14D, showing lasting β1-adrenergic receptor

25   antagonism induced by the TM VII peptide fragment

Figures 14E to 14H show the results of a control
experiment. Baseline cardiac parameters were 240
beats/min and blood pressure 130-125/80 (Fig. 14E). Fig.
14F shows the response to 1 mg/Kg isoproterenol,

30   resulting in reduced baseline blood pressure 125/60
characteristic of β1-adrenergic receptor activation.
Administration of peptide vehicle (Buffer A + 10% DMSO)
slightly reduced blood pressure to 140/50 but did not

71

change spontaneous cardiac activity (Fig. 14G).

After baseline parameters were reestablished,
exposure of the animal to 1 mg/Kg isoproterenol showed
characteristic heart beat and blood pressure changes
5   (Fig. 14H) with no attenuation of the drug's initial
effect.

C: Inhibition of α1A-adrenergic receptor activity

After a period of recording baseline cardiac
function in an awake and freely-mobile rat (360 beats/min
10   with systolic/diastolic blood pressure of 130/90, as seen
in Figure 15A), the rat was given 5 mg/Kg phenylephrine
by rapid IV bolus. Heart rate was reduced to 240
beats/min, with blood pressure rising to 180/140,
reflecting a drug-induced vasoconstriction effect (Fig.
15   15B).

After an interval to allow baseline parameters to be
reestablished, 100 ml of 5 mg/ml peptide
VFKVIFWLGYFNSCVN, a fragment of the α1A-adrenergic
receptor TM VII peptide was administered intravenously.
20   As seen in Figure 15C, heart rate was reduced to 240
beats/min before recovery to 420 beats/min, during which
time there was a significant, transient drop in blood
pressure to 130-120/60.

After baseline parameters were again reestablished,
25   a further 5 mg/Kg phenylephrine was administered. The
response to phenylephrine was delayed and attenuated
indicating lasting α1A-adrenergic receptor antagonism
induced by the TM VII peptide fragment (Figure 15D).
Figures 15E-15G show the results of a control experiment
30   in the same rat. Administration of saline resulted in an
unexpected transient increase in blood pressure from
150/100 to 180/100, with no change in heart rate, before
stabilising to baseline values (Figure 15E).

Administration of peptide vehicle had no significant

72

effect on heart rate, but lowered blood pressure
marginally from 150/100 to 140/80 (Fig. 15G). Subsequent
administration of 5 mg/Kg phenylephrine showed no
diminution of effect and reduced heart rate to 240
5   beats/min with blood pressure rising to 180/140 (Fig.
15F).

As a comparison, the effect of prasozin, a classical
α1A-adrenergic receptor antagonist, was examined (Figures
15H to 15K).

10 Prasozin (1 mg/Kg by rapid IV bolus) had an effect
on heart rate and blood pressure (Figure 15J) similar to
that of the antagonist TM VII peptide fragment and also
caused attenuation of the response to a subsequent
administration of the agonist phenylephrine (Fig. 15K).

15 Example 6 - Inhibition of vasopressin V2 receptor *in vivo*

A: **METHODS**

Rats and surgery: Sprague Dawley rats were obtained from
Charles River (220-230 g). Rats were acclimizatized for
48 h prior to experiments. Rats were anesthesized with
20 halothane and nephrectomized (right kidney) and placed
back into the vivarium for seven days. Following this
post-operative recovery time, rats weighed 250-270 g.
Rats were then anesthesized with sodium pentobarbital at
a dose of 36 mg/ kg (i.p.) and maintained under
25 anesthesia for the duration of the experiment with 3 mg
pentobarbital doses as necessary.

A catheter was placed in the right carotid artery
(PE 50) for measuring blood pressure, one in the left
jugular vein (PE 60) for injection of vehicle, peptide,
30 or drugs and one in the left ureter (PE50) for collecting
urine.

Following surgery, rats were stabilized for 45 min.
Mean arterial pressure was measured for 15 min
(baseline), at which time various drugs were injected via

73

jugular vein and mean arterial pressure (MAP) and urine
output recorded.

V2 antagonist Peptide: V2 receptor peptide antagonism and
its effects on MAP and urine output was assessed by

5   single bolus dose of 1 mg peptide (V2-TM VII:
LMLLASLNSCTNPWIY) in 200 ml vehicle (water with 10% DMSO
and protease inhibitors).

Bolus injection of the V2-TM VII peptide (V2 AT)
resulted in a marked increase in urine output, from

10   baseline urine flow of 1100 ml/15 min to 1900 ml/15 min,
which was sustained for 45 min. (Figure 16). In
comparison, injection of the vehicle alone had only a
small effect on increasing urine output (Figure 16).
These data show that receptor-subtype specific TM

15   peptides act as antagonists of V2 receptors.

Example 7 - Inhibition of HIV infectivity by antagonists
of the CCR5 receptor

A: METHODS

CCR5 Peptide Antagonist Treatments: 10 mg of peptide

20   (CCR5-TM 1: LYSLVFIFGFVGN-NH2) was dissolved in 500 ml of
DMSO, and 50 ml was used to pretreat 1 ml of cultured
cells (4 X 10x6 cells/well) for ½ h. Peptide
concentration at this stage was 0.5 mg/ml. Peptide
concentration was then diluted in half upon addition of

25   virus for 2 h, in a total assay volume of 2 ml.

HIV-1 Infectivity Assay As Assessed By HIV-RT Activity:
HIV-1 Infectivity Assay was performed according to
methods described by Mark A. Wainberg (Soudeyns et al.,
Antimicrobial Agents and Chemotherapy **35**, 1386-1390,

30   1991).

HIV-IIIB isolate of HIV-1 was employed because of
its high infectiousness. Briefly, human PBMC cells were
infected at a multiplicity of infection of 0.1. To
determine the levels of inhibition of HIV-1 adsorption,

74

by CCR5-TM1, PBMC cells were pretreated for 1/2 h with
the peptide, exposed to the virus for 2 h and viral
infection was assessed 7 days post-infection by
estimation of viral cDNA by RT-PCR levels in culture

5   *HIV-1 Infectivity Assay As Assessed By Viral P24-antigen*
     Production The CCR5-TM peptide antagonist (CCR5-TM 1:
     LYSLVFIFGFVGN-NH2) was tested for anti-M tropic virus
     activity as described in Brennan et al., (1995), Antiviral
     Research, **26,**173 and Taylor et al., (1995), Antiviral

10   Research, **28,** 159.
     B: Peptide inhibition of cellular adsorption and uptake
     of HIV as assessed by RT-activity: In human PBMC cells
     pretreated with CCR5 TM1, the HIV reverse transcriptase
     activity was 26m757.5 $\pm$ 4051 cpm (mean of triplicate

15   wells), compared to 128,792 $\pm$ 11996 cpm (mean of
     triplicate wells) for non-peptide treated cells. These
     data indicate 79% inhibition of HIV infection by the CCR5
     peptide antagonist (Fig. 17A).
     C: **Peptide inhibition of HIV cellular adsorption and**

20   **uptake as assessed by P24-antigen production:** In PBMC
     cells pretreated with CCR5-TM1, the HIV P24 level was
     4730 pg/ml compared to 20960 pg/ml for non-peptide
     treated cells. These data indicate 77% inhibition of HIV
     infection by the CCR5 peptide antagonist (Fig. 17B).

25   These data show that CCR5-TM peptide acted as an
     antagonist of the CCR5 receptor and inhibited HIV
     infection.
     Example 8 - Inhibition of EGF-mediated tyrosine kinase
     activity

30   **A: METHODS**
     Cell Culture: The human A431 cell line (ATCC CRL 1555)
     was established from an epidermoid carcinoma of a 85 year
     old female patient. It expresses an extremely high number
     of EGF receptors on its cell surface (3 x10E6/cell), due,

at least in part, to the amplification of EGF receptor
DNA sequences (30-fold).

EGF receptor tyrosine kinase enzyme assay: The Biotrak*
assay system and kit by Amersham Life Science was used.
5   In brief, the system is designed to detect epidermal
growth factor receptor tyrosine kinase enzyme activity in
solubilized tissues and cells. Enzyme present in the
samples will catalyze the transfer of the g-phosphate of
adenosine-5^t-triphosphate to the tyrosine group on a
10   peptide which is specific for EGFr tyrosine kinase
domain. Specific detection of the enzyme is further
assured by using epidermal growth factor to activate the
EGF receptor tyrosine kinase enzyme activity. Thus EGF
dependent tyrosine kinase activity may be determined from
15   the difference between the enzyme activity in the
presence or absence of added epidermal growth factor.
The assay is performed at pH 7 .4 in Hepes buffer with
MgCl$_2$ as the essential metal ion. The assay will give
linear incorporation of phosphorus-32· into substrate
20   peptide corresponding to at least 20% of ATP
incorporated, providing samples are suitably diluted.
Phosphorylated peptide is separated on binding paper.
After washing the paper, the extent of phosphorylation
may be detected by scintillation counting.
25   A solubilized membrane preparation was prepared from
A431 cells maintained in culture as a monolayer, and
preincubated for 30 min at 30 °C with various
concentrations of a peptide derived from the TM domain of
the EGF-erb3 receptor (EGFR3-TM: LTVIAGLVVIF) or with
30   peptides derived from TM domains of other receptors (D2-
TM VII-TWLGYVNSA; GABA-A: GIFNLVYW) prior to tyrosine
kinase assay.

**B: EGF-erb3 receptor TM peptide inhibited EGF mediated
tyrosine kinase activity.** The EGFr peptide antagonist

76

(LTVIAGLVVIF) inhibited EGF mediated tyrosine kinase
activity in a dose-dependent manner, in comparison to a
peptide derived from GABA TM domain (GIFNLVYW) (Fig. 18).
Peptide D2-TM VII (TWLGYVNSA) had a similar lack of

5   effect on EGF mediated tyrosine kinase activity (data not
shown).

Example 9 - Inhibition of bacterial growth

A: **METHODS**

Peptide treatments: A peptide derived from *E. Coli* ATPase

10   Fo b subunit, GQAIAFVLFVL and the peptide derived from *E.
Coli* ATPase Fo c subunit, LAAIGAAIGIGILG were tested for
antimicrobial activity in comparison to a peptide derived
from the GABA-A ion channel (GIFNLVYW), and a peptide
derived from the D2 dopamine receptor (D2-TM VII-

15   TWLGYVNSA). 5 mg of each peptide was dissolved in DMSO
and diluted with water (DMSO concentration was 10% of the
final volume). When tested alone, 50 ml of peptide
solution was used for each 500 ml culture. When tested
in combination, 25 ml of each peptide solution was used

20   for each 500 ml culture.

Gram negative *E. Coli* culture and antimicrobial assay: *E.
coli* strain LE392 was grown in LB medium to a density of
O.D.600 between .8-1.0. A 10:1 dilution was made for a
final volume of 500 ml. 50 ml of test peptide (5 mg/ml

25   stock concentration) was added to the culture (0.5 ug/ul,
final peptide concentration) which was then grown at 37 C
for 2 h. 50 ml of the culture was then plated on to LB
plates at 10^{-6} dilution. Plates were then incubated
overnight and colonies counted the next morning. The

30   remaining culture was stored at 4 °C overnight. 50 ml of
this culture was then plated the following day on to LB
plates at 10^{-6} dilution. Plates were incubated overnight
and colonies counted next morning.

B: **Antimicrobial activity of TM peptides derived from**

77

the Fo c and b subunits of the Gram negative *E. coli*
bacteria. Peptides derived from the Fo b and Fo c sub-
units, used either singly or in combination, suppressed
the growth of E. coli. In one experiment, when *E. coli*
5   cultures were treated with a combination of the peptides
derived from the Fo b and c subunits, there were 9
colonies compared to 31 for vehicle treated cells, and 29
for cells treated with a peptide derived from the GABA-A
channel subunit (Fig. 19). In a further experiment,
10   peptides derived from the Fo b and c subunits used in
combination resulted in total killing of bacteria.

These data show that transmembrane peptides derived
from bacterial transporter proteins act as potent
antimicrobial agents.

15   Example 10 - Inhibition of cocaine-mediated dopamine
release

A: METHOD

In vivo microdialysis to measure DA transporter function:
Male Wistar rats (Charles River Canada; 200-250 g) were
20   individually caged in environmental rooms under constant
conditions of temperature, humidity and 12 hr light-dark
cycles. Food was available ad libitum. Animals were
handled and weighed daily to minimize stress on
experimental days. Rats were implanted with
25   intracerebral guide cannulae (Plastic Products Company,
Roanoke, VA, U.S.A.) for the microdialysis probes
(Carnegie Medicin, Sweden) under anaesthesia with
ketamine (66 mg/kg) and pentobarbital (22 mg/kg). The
cannula was inserted into the medial nucleus accumbens
30   (coordinates relative to bregma: A +1.5, L +1.3, V +7.6,
Paxinos and Watson, 1982) or caudate nucleus
(coordinates relative to bregma: A +1.6, L +2.3, V -3.8)
for microdialysis sampling. The animals were allowed to
recover for a minimum of 3 days before sampling studies

78

were conducted. At the end of the experiments, probe placement was verified anatomically in each case by sectioning the frozen brain using a microtome-cryostat.

Results reported are only from those animals in which
5   the probe was confirmed to be in the medial part of the nucleus accumbens or caudate nucleus histologically.

On the day of the experiment, the steel insert from the guide cannula was replaced by the dialysis probe (2 mm, CMA/12, Carnegie Medicin, Sweden) and perfused with
10 artificial CSF (NaCl 145 mM, KCl 2.7 mM, $CaCl_2.2H_2O$ 1.2 mM, $MgCl_2$ 1.0 mM, Na_2HPO_4 2 mM, ascorbic acid 0.2 mM, pH 7.4) at a rate of 1 ml/min. Perfusion in the awake, unrestrained and mobile animals was continued for 3-4 hours until the basal efflux of dopamine and its
15 metabolites were stable for 3 consecutive measurements. Dialysate was collected over 30 min periods and injected directly into a HPLC system equipped with a Biophase ODS 5 mm, 4.6 x 250 mm column, Waters 590 pump with U6K injector and ESA 5100A electrochemical detector with
20 Model 5011 analytical cell for measurement of DA, DOPAC and HVA. The mobile phase consisted of 50 mM sodium phosphate monobasic, 0.5 mM EDTA, 1.8 mM sodium octyl sulfonate, 14 % methanol, with pH adjusted to 3.50 with phosphoric acid. Sensitivity of dopamine detection was 2
25 pg. The percentage recovery of dopamine through the dialysis cannula was calculated each time.

B: Inhibition of cocaine-mediated dopamine release

An antagonist peptide for the dopamine transporter
30 (DAT) was made based on the amino acid sequence of TM-12 (DAT-TM XII:ALGWIIATS). In animals given cocaine (5 mg/kg i.p.) there was a characteristic rapid release of dopamine measured by microdialysis sampling in the striatum, as shown in Fig. 20 (solid circles).

79

Pretreatment with the antagonist peptide for the dopamine
transporter (70 mg given intracerebroventricularly by
slow infusion in 7 ml of buffered saline 12 min before
injection of cocaine) resulted in the complete abolition

5   of the dopamine release mediated by cocaine (Fig. 20,
open circles). Intracerebroventricular injection of the
dopamine transporter antagonist peptide alone in doses of
70 mg or 98mg had no effect on dopamine release in
striatum (Fig. 21).

10   In animals given cocaine (5 mg/kg i.p.), there was a
characteristic rapid release of dopamine measured by
microdialysis sampling in the nucleus accumbens, as shown
in Fig. 22, solid circles. Pretreatment with the
antagonist peptide for the dopamine transporter (150 mg

15 given intracerebroventricularly by slow infusion in 7 ml
of buffered saline 12 min before injection of cocaine)
resulted in marked attenuation of the dopamine release
mediated by cocaine (Fig. 22, open circles).

These data show that transmembrane peptides derived

20 from the dopamine transporter act are effect to
counteract the effect of cocaine on the transporter.
Example 11 - Inhibition of HIV infectivity by antagonists
of the CD4 receptor
A: METHODS

25 Peptide inhibition of HIV cellular adsorption and uptake
as assessed by P24-antigen production. In cells
pretreated with the CD4-TM peptide antagonist
LIVLGGVAGLLLF, for 1 hour, the HIV P24 level was 14970
pg/ml compared to 20960 pg/ml for non-peptide treated

30 cells. These data indicate 29% inhibition of HIV
infection by the CD4-TM peptide antagonist (Fig. 23).

These data show that the CD4-TM peptide acted as an
inhibitor of HIV infection.

The present invention is not limited to the features

80

of the embodiments described herein, but includes all
variations and modifications within the scope of the
claims.

REFERENCES

Baldwin, J.M., (1993) *EMBO J.*, v. 12, pp. 1693-1703.

Barnard, E.A., (1995), *"The Molecular Biology of GABAA Receptors and Their Structural Determinants" in GABAA Receptors and Anxiety: From Neurobiology to Treatment"*, Eds. Biggio et al., Raven Press, N.Y.

Boni-Schnetzler et al., (1987), P.N.A.S. USA, v. 84, pp. 7832-7836.

Bormann, B.-J., et al., (1989), *J. Biol. Chem.*, v. 264, pp. 4033-4037.

Dragic et al., (1996), *Nature*, v. 381, pp. 667-673.

Engelman et al., (1986), *Ann. Rev. Biophys. Chem.*, v. 15, pp. 321-352.

Furthmayr et al., (1976), *Biochemistry*, v. 15, p. 1137.

Hawes et al., (1994), *J. Biol. Chem.*, v. 269, pp. 15776-15785.

Kobilka et al., (1988), *Science*, v. 240, pp. 1310-1316.

Kraus et al., (1989), *P.N.A.S. USA*, v. 86, pp. 9193-9197.

Kyte et al., (1982), *J. Biol. Chem*, v. 157.

Lemmon et al., (1992), *J. Biol. Chem*, v. 267, pp. 7683-7689.

Liu et al., (1995), *J. Biol. Chem.*, v. 270, pp. 19532-19539.

Lofts et al. (1993), *Oncogene*, v. 8, pp. 2813-2820.

Luttrell et al., (1993),*Science*, v. 259, p. 1453.

Maggio et al., (1993), *Proc. Natl. Acad. Sci U.S.A.*, v. 90, pp. 3103-3107.

Ng et al., (1993), *Biochemistry*, v. 32, pp. 11727-11733.

Ng et al., (1994a), *J. Neurochem.*, v. 63, pp. 1589-1595.

Ng et al., (1994b), *Eur. J. Pharmacol.*, v. 267, pp. 7-19.

82

O'Dowd, (1993), *J. Neurochem.*, v. 60, p. 804.

Okamoto et al., (1991), *Cell*, v. 67, p. 723.

Schofield et al., (1987), Nature, v. 328, pp. 221-227.

Seeman, P., (1995), *Scientific American - Science & Medicine*, vol. 2, pp. 28-37.

Suryanarayana et al., (1992), *J. Biol. Chem.*, v. 267, pp. 21991-21994.

O'Dowd et al., (1991), *Encyclopaedia of Human Biology*, v. 1, pp. 81-92, Academic Press.

Lambert et al., (1996), *Proc. Natl. Acad. Sci. USA*, v. 93, pp. 2186-2191.

83

TABLE 1A - G PROTEIN-COUPLED RECEPTORS

Receptor	Accession #	Receptor	Accession #
Adenosine A_1	P30542	Chemokine CXCR1	L19591*
Adenosine A_{2A}	P29274	Chemokine CXCR2	M73969*
Adenosine A_{2B}	P29275	Chemokine CXCR3	U32674*
Adenosine A_3	P33765	Chemokine CXCR4	M86739*
Adrenergic α_{1A}	P25100	Cholecystokinin CCK_A	P32238
Adrenergic α_{1B}	P35368	Cholecystokinin CCK_B	P32239
Adrenergic α_{1D}	M60654*		
Adrenergic α_{2A}	P08913	Dopamine D1	P21728
Adrenergic α_{2B}	P18089	Dopamine D2	P14416
Adrenergic α_{2C}	P18825	Dopamine D3	P35462
Adrenergic β_1	P08588	Dopamine D4	P21917
Adrenergic β_2	P07550	Dopamine D5	P21918
Adrenergic β_3	P13945		
		Endothelin ET_A	P25101
Adrenomedullin	L09249*	Endothelin ET_B	P24530
Anaphylatoxin C3a	U28488*	Follicle-stimulating	P23945
Anaphylatoxin C5a	P21730	hormone	
Angiotensin AT_{1A}	X62295*	Formyl-peptide FPR1	P21462
Angiotensin AT_{1B}	Q13725	Formyl-peptide FPR2	M84562*
Angiotensin AT_2	P50052		
		Galanin	P47211
Bombesin BB_1	U37058*		
Bombesin BB_2	M57922*	Gastrin receptor	P32239
Bombesin BB_3	P32247		
		Gonadotropin-releasing	P30968
Bradykinin B_1	P46663	hormone	
Bradykinin B_2	P30411		
		Histamine H_1	P35367
Calcitonin-gene related peptide 1	Q16602	Histamine H_2	P25021
Cannabinoid CB1		Lutropin-	P22888
Cannabinoid CB2	P21554	choriogonadotropin	
	P34972	hormone (LH-CG)	
Chemokine CCR1			
Chemokine CCR2	P32246	Lysophosphatidic acid	U76385*
Chemokine CCR3	P41597		
Chemokine CCR4	P51677	Melanocortin MC1	X65634*
Chemokine CCR5	P51679	Melanocortin MC2	Q01718
	P51681	Melanocortin MC3	P41968
		Melanocortin MC4	P32245
		Melanocortin MC5	P33032

84

TABLE 1B - G-PROTEIN COUPLED RECEPTORS

Receptor	Accession #	Receptor	Accession #
Melatonin ML_{1A}	P48039	Prostanoid EP_1	P34995
Melatonin ML_{1B}	P49286	Prostanoid EP_2	P43116
		Prostanoid EP_3	P43115
Muscarinic Acetylcholine M1	P11229	Prostanoid EP_4	P35408
		Prostanoid DP	D29764*
Muscarinic Acetylcholine M2	P08172	Prostanoid FP	P43088
		Prostanoid IP	P43119
Muscarinic Acetylcholine M3	P20309	Prostanoid TP	D38081*
Muscarinic Acetylcholine M4	P08173	Protease-activated 1	M62424*
		Protease-activated 2	Z35158*
Muscarinic Acetylcholine M5	M80333*		
		Purinoceptor PS_{Y1}	X73268*
		Purinoceptor $P2_{Y2}$	P41231
Neurokinin NK1 (substance P)	J05097*	Purinoceptor $P2_{Y3}$	X98283*
		Purinoceptor $P2_{Y4}$	U40223*
Neurokinin NK2 (substance K)	P21452	Purinoceptor $P2_{Y5}$	L06109*
		Purinoceptor $P2_{Y6}$	D63665*
Neurokinin NK3 (neuromedin K)	P29371	Purinoceptor $P2_{Y7}$	U41070*
Neurokinin NK4	M84605*	Rhodopsin	P08100
Neuropeptide Y Y1	P25929	Serotonin $5\text{-}HT_{1A}$	P08908
Neuropeptide Y Y1-like	U58367*	Serotonin $5\text{-}HT_{1B}$	P28222
Neuropeptide Y Y2	P49146	Serotonin $5\text{-}HT_{1D}$	P28221
Neuropeptide Y Y4	P50391	Serotonin $5\text{-}HT_{1E}$	P28566
Neuropeptide Y Y5	Q61212	Serotonin $5\text{-}HT_{1F}$	P30939
		Serotonin $5\text{-}HT_{2A}$	P28223
Neurotensin NTR1	P30989	Serotonin $5\text{-}HT_{2B}$	P41595
Neurotensin NTR2	X97121*	Serotonin $5\text{-}HT_{2C}$	P28335
		Serotonin $5\text{-}HT_4$	U20907*
Opioid δ	P41143	Serotonin $5\text{-}HT_{5A}$	P47898
Opioid κ	P41145	Serotonin $5\text{-}HT_{5B}$	X69867*
Opioid μ	P35372	Serotonin $5\text{-}HT_6$	P50406
Orphanin	P41146	Serotonin $5\text{-}HT_7$	P34969
Oxytocin	P30559	Somatostatin sst_1	P30872
		Somatostatin sst_2	P30874
Platelet-activating factor	P25105	Somatostatin sst_3	P32745
		Somatostatin sst_4	P31391
		Somatostatin sst_5	P35346
		Thyrotropin-releasing hormone	M37490*

TABLE 1C - G-COUPLED PROTEIN RECEPTORS

Receptor	Accession #
Thyrotropin-stimulating hormone (TSH)	M29957*
Vasopressin V_{1A}	P37288
Vasopressin V_{1B}	P47901
Vasopressin V_2	P30518
Secretin	P47872
Calcitonin	P30988
Parathyroid hormone	P49190
Parathyroid hormone related peptide	Q03431
VIP	P32241
Glucagon	P47871
Glucagon-like peptide 1	P43220
Growth hormone releasing hormone	Q02643
Pituitary adenylate cyclase activating polypeptide	P41586
Corticotropin releasing factor	Q13324
Gastric inhibitory polypeptide	P48546
Calcium sensing	P41180

86

TABLE 2

DOPAMINE D2 RECEPTOR, Human

443 Amino acids

ACCESSION: P14416

FEATURES

DOMAIN	1	37	EXTRACELLULAR (POTENTIAL).
TRANSMEM	38	60	1 (POTENTIAL).
DOMAIN	61	71	CYTOPLASMIC (POTENTIAL).
TRANSMEM	72	97	2 (POTENTIAL).
DOMAIN	98	108	EXTRACELLULAR (POTENTIAL).
TRANSMEM	109	130	3 (POTENTIAL).
DOMAIN	131	151	CYTOPLASMIC (POTENTIAL).
TRANSMEM	152	174	4 (POTENTIAL).
DOMAIN	175	186	EXTRACELLULAR (POTENTIAL).
TRANSMEM	187	210	5 (POTENTIAL).
DOMAIN	211	373	CYTOPLASMIC (POTENTIAL).
TRANSMEM	374	397	6 (POTENTIAL).
DOMAIN	398	405	EXTRACELLULAR (POTENTIAL).
TRANSMEM	406	429	7 (POTENTIAL).
DOMAIN	430	443	CYTOPLASMIC (POTENTIAL).

SEQUENCE

```
MDPLNLSWYD DDLERQNWSR PFNGSDGKAD RPHYNYYATL LTLLIAVIVF GNVLVCMAVS
REKALQTTTN YLIVSLAVAD LLVATLVMPW VVYLEVVGEW KFSRIHCDIF VTLDVMMCTA
SILNLCAISI DRYTAVAMPM LYNTRYSSKR RVTVMISIVW VLSFTISCPL LFGLNNADQN
ECIIANPAFV VYSSIVSFYV PFIVTLLYVI KIYIVLRRRR KRVNTKRSSR AFRAHLRAPL
KGNCTHPEDM KLCTVIMKSN GSFPVNRRRV EAARRAQELE MEMLSSTSPP ERTRYSPIPP
SHHQLTLPDP SHHGLHSTPD SPAKPEKNGH AKDHPKIAKI FEIQTMPNGK TRTSLKTMSR
RKLSQQKEKK ATQMLAIVLG VFIICWLPFF ITHILNIHCD CNIPPVLYSA FTWLGYVNSA
VNPIIYTTFN IEFRKAFLKI LHC
```

87

TABLE 3

Accession #

IMMUNOGLOBIN super family
CD4   P01730

TNF/NGF superfamily
TNF-α1   P19438
TNF-α2   P20333
EGF erb1   P00533
IL-1   P14778
CD95   P25445

EGF-TM7 family
CD97   P48960

TM4 superfamily
CD9   P21926

C Type Lectin superfamily
CD 94

Ion channels
GABA-A   P14867
p-glycoprotein   P08183
bacterial ATPase   Z26850*

Tyrosine kinase
Fgr1   P11362
Fgr2   P21802
Vgr1   P17948
VGR2   P35968
TrkA   P04692

TABLE 4A

**HUMAN CC CHEMOKINE
(CCR5) RECEPTOR**

Transmembrane Domain 1:
LLPPLYSLVFIFGFVGNMLVILILINC
(Sequence ID NO:120)
Transmembrane Domain 2:
LLNLAISDLFFLLTVPFWAHY
(Sequence ID NO:121)
Transmembrane Domain 3:
LLTGLYFIGFFSGIFFIILLTI
(Sequence ID NO:122)
Transmembrane Domain 4:
VTFGVVTSVITWVVAVFASLPGIIF
(Sequence ID NO:123)
Transmembrane Domain 5:
VILGLVLPLLVMVICYSGIL
(Sequence ID NO:124)
Transmembrane Domain 6:
LIFTIMIVYFLFWAPYNIVLLLNTF
(Sequence ID NO:125)
Transmembrane Domain 7:
AMQVTETLGMTHCCINPIIYAFVG
(Sequence ID NO:126)

**HUMAN FUSIN (CXCR4)
RECEPTOR**

Transmembrane Domain 1:
FLPTIYSIIFLTGIVGNGLVILVMG
(Sequence ID NO:127)
Transmembrane Domain 2:
LSVADLLPVITLPFWAVDAV
(Sequence ID NO:128)
Transmembrane Domain 3:
AVHVIYTVNLYSSVLILAFISL
(Sequence ID NO:129)
Transmembrane Domain 4:
VVYVGVWIPALLLTIPDFIFA
(Sequence ID NO:130)
Transmembrane Domain 5:
FQHIMVGLILPGIVILSCYCII
(Sequence ID NO:131)
Transmembrane Domain 6:
TVILILAFFACWLPYYIGISI
(Sequence ID NO:132)
Transmembrane Domain 7:
ITEALAFFHCCLNPILYAFLG
(Sequence ID NO:133)

HUMAN 5HT1A RECEPTOR
Transmembrane Domain 1:
QVITSLLLGTLIFCAVLGNACVVAAIAL
(Sequence ID NO:134)

Transmembrane Domain 2:
LIGSLAVTDLMVSVLVLPMAALYQVL
(Sequence ID NO:135)
Transmembrane Domain 3:
DLFIALDVLCCTSSILHLCAIAL
(Sequence ID NO:136)
Transmembrane Domain 4:
AAALISLTWLIGFLISIPPMLGW
(Sequence ID NO:137)
Transmembrane Domain 5:
DHGYTIYSTFGAFYIPLLLMLVLYG
(Sequence ID NO:138)
Transmembrane Domain 6:
TLGIIMGTFILCWLPFFIVALVL
(Sequence ID NO:139)
Transmembrane Domain 7:
LLGAIINWLGYSNSLLNPVIYAY
(Sequence ID NO:140)

HUMAN MU OPIOID RECEPTOR

Transmembrane Domain 1:
MITAITIMALYSIVCVVGLFGNFLVMYV
IV(Sequence ID NO:141)
Transmembrane Domain 2:
TATNIYIFNLALADALATSTLP
(Sequence ID NO:142)
Transmembrane Domain 3:
IVISIDYYNMFTSIFTLCTMSV
(Sequence ID NO:143)
Transmembrane Domain 4:
WILSSAIGLPVMFMATT
(Sequence ID NO:144)
Transmembrane Domain 5:
ICVFIFAFIMPVLIITVCYGLMI
(Sequence ID NO:145)
Transmembrane Domain 6:
MVLVVVAVFIVCWTPIHIYVII
(Sequence ID NO:146)
Transmembrane Domain 7:
TFQTVSWHFCIALGYTN
(Sequence ID NO:147)

**HUMAN MELANOCYTE STIMULATING
HORMONE (MSH) RECEPTOR**

Transmembrane Domain 1:
VSISDGLFLSLGLVSLVENALVVATIA
(Sequence ID NO:148)
Transmembrane Domain 2:
MYCFICCLALSDLLVSGT NVL
(Sequence ID NO:149)
Transmembrane Domain 3:
VIDVITCSSMLSSLCFLGAIAV
(Sequence ID NO:150)

TABLE 4A (Continued)

Transmembrane Domain 4:
AVAAIWVASVVFSTLFIAYYD(151)
Transmembrane Domain 5:
LVVFFLAMLVLMAVLYVHML(152)
Transmembrane Domain 6:
VTLTILLGIFFLCWGPFFLHLTLIVL
(153)
Transmembrane Domain 7:
FNLFLALIICNAIIDPLIYAF(154)

**HUMAN ANGIOTENSIN AT2 TYPE 1
RECEPTOR**
Transmembrane Domain 1:
FVMIPTLYSIIFVVGIFGNSLVVIV
(Sequence ID NO:155)
Transmembrane Domain 2:
VFLLNLALADLCFLLTLPLWAVY
(Sequence ID NO:156)
Transmembrane Domain 3:
IASASVSFNLYASVFLLTCLSI
(Sequence ID NO:157)
Transmembrane Domain 4:
TMLVAKVTCIIIWLLAGLASLP
(Sequence ID NO:158)
Transmembrane Domain 5:
PIGLGLTKNILGFLFPFLIILTS
(Sequence ID NO:159)
Transmembrane Domain 6:
IIMAIVLFFFFSWIPHQIFTF
(Sequence ID NO:160)
Transmembrane Domain 7:
IADIVDTAMPITICIAYFNNCL
(Sequence ID NO:161)

90

TABLE 4B

HUMAN NEUROPEPTIDE NPY5 RECEPTOR

Transmembrane Domain 1:
QYFLIGLYTFVSLLGFMGNLLIL
(Sequence ID NO:162)
Transmembrane Domain 2:
TVNFLIGNLAFSDILVVLFCS
(Sequence ID NO:163)
Transmembrane Domain 3:
IMPFLQCVSVLVSTLILISIAI
(Sequence ID NO:164)
Transmembrane Domain 4:
FLIATVWTLGFAICSPLPVFHS
(Sequence ID NO:165)
Transmembrane Domain 5:
FTISLLLVQYILPLVCLTVSHT
(Sequence ID NO:166)
Transmembrane Domain 6:
LTILILVFAVSWMPLHLFHVVT
(Sequence ID NO:167)
Transmembrane Domain 7:
LVYCICHLLGMMSCCLNPILYGFL
(Sequence ID NO:168)

HUMAN MDR1-P Glycoprotein

Transmembrane Domain 1:
VVGTLAAIIHGAGLPLMMLVF
(Sequence ID NO:169)
Transmembrane Domain 2:
GIGAGVLVAAYIQVSFWCLAA
(Sequence ID NO:170)
Transmembrane Domain 3:
IGMFFQSMATFFTGFIVGFT
(Sequence ID NO:171)
Transmembrane Domain 4:
LVILAISPVLGLSAAVWAKII
(Sequence ID NO:172)
Transmembrane Domain 5:
ISIGAAFLLIYASYALAFWYG
(Sequence ID NO:173)
Transmembrane Domain 6:
YSIGOVLTVFFSVLIGAFSVG
(Sequence ID NO:174)
Transmembrane Domain 7:
FVVGVFCAIINGGLQPAFAII
(Sequence ID NO:175)
Transmembrane Domain 8:
LLFLALGIISFITFFLQGFTF
(Sequence ID NO:176)
Transmembrane Domain 9:
LAVITQNIANLGTGIIISFIY
(Sequence ID NO:177)
Transmembrane Domain 10:
GWQLTLLLLAIVPIIAIAGVV
(Sequence ID NO:178)
Transmembrane Domain 11:
IFGITFSFTQAMMYFSYAGCF
(Sequence ID NO:179)
Transmembrane Domain 12:
LLVFSAVVFGAMAVGQVSSF
(Sequence ID NO:180)

We claim:

1.   An antagonist for inhibiting the function of a
prokaryotic or eukaryotic integral membrane protein
having at least one transmembrane domain, the antagonist
comprising a peptide having an amino acid sequence of at
least four consecutive amino acids selected from the
amino acid sequence of said at least one transmembrane
domain.

2.   The antagonist of claim 1 comprising a peptide having
an amino acid sequence of at least ten consecutive amino
acids selected from the amino acid sequence of said at
least one transmembrane domain.

3.   The antagonist of claim 1 comprising a peptide
having an amino acid sequence of at least fifteen
consecutive amino acid selected from the amino acid
sequence of said at least one transmembrane domain.

4.   The antagonist of claim 1 comprising a peptide
having an amino acid sequence of at least twenty
consecutive amino acids selected from the amino acid
sequence of said at least one transmembrane domain.

5.   The antagonist of claim 1 comprising a peptide
having the amino acid sequence of said at least one
transmembrane domain or an effective fragment or analogue
thereof.

6.   The antagonist of any of claims 1 to 5 wherein the
integral membrane protein is a prokaryotic or eukaryotic
plasma membrane protein.

7. The antagonist of any of claims 1 to 5 wherein the

integral membrane protein is a prokaryotic or eukaryotic intracellular membrane.

8.   The antagonist of claim 6 wherein the integral membrane protein is a mammalian plasma membrane protein.

9.   The antagonist of claim 1 wherein the integral membrane protein has a plurality of transmembrane domains and wherein the peptide comprises the amino acid sequence of any one of said plurality of transmembrane domains or a fragment or analogue thereof.

10.   The antagonist of any of claims 1 to 9 wherein the integral membrane protein is a human protein.

11.   The antagonist of claim 8 wherein the integral membrane protein is a protein selected from the group consisting of
        (a)   a G-protein coupled receptor;
        (b)   a tyrosine kinase receptor;
        (c)   an ion channel;
        (d)   an ion channel receptor;
        (e)   a channel protein;
        (f)   an antigen receptor;
        (g)   a transporter protein; and
        (h)   an immune receptor.

12.   The antagonist of claim 11 wherein the integral membrane protein is a G-protein coupled receptor selected from the group consisting of
        (a)   a dopamine receptor;
        (b)   an adrenergic receptor;
        (c)   an adenosine receptor;
        (d)   a vasopressin type 2 receptor;

(e)   a chemokine receptor;

(f)   a serotonin receptor;

(g)   an opioid receptor;

(h)   an angiotensin receptor;

(i)   a neuropeptide receptor; and

(j)   a melanocyte stimulating hormone receptor.

13.   The antagonist of claim 12 wherein the integral membrane protein is a D1 dopamine receptor and the antagonist is a peptide selected from the group consisting of

(a)   ILTACFLSLLILSTLLGNTLVCAAV;

(b)   FFVISLAVSDLLVAVLVMPWKAVAEIA;

(c)   NIWVAFDIMCSTASILNLCVISVD;

(d)   AAFILISVAWTLSVLISFIPVQLSW;

(e)   TYAISSSVISFYIPVAIMIVTYTRI;

(f)   TLSVIMGVFVCCWLPFFILNCILPFC;

(g)   FDSNTFDVFVWFGWANSSLNPIIYAFNAD and

(h)   an effective analogue or fragment of (a) to
       (g).

14.   The antagonist of claim 12 wherein the integral membrane protein is a D2 dopamine receptor and the antagonist is a peptide selected from the group consisting of

(a)   ATLLTLLIAVIVFGNVLVCMAVS;

(b)   LIVSLAVADLLVATLMPWVVYLEVV;

(c)   IVFTLDVMMCTASILNLCAISI;

(d)   VTVMISIVWVLSFTISCPLLFGL;

(e)   PAFVVYSSIVSFYVPFIVTLLVYI;

(f)   MLAIVLGVFIICWLPFFITHILN;

(g)   VLYSAFTWLGYVNSAVNPIIYTTF and

(h) an effective analogue or fragment of (a) to
    (g).

94

15. The antagonist of claim 12 wherein the integral
membrane protein is a D2 dopamine receptor and the
antagonist is a peptide selected from the group
consisting of
   (a)   YATLLTLLIAVIVFGNVLVC;
   (b)   VSLAVADLLVATLVMPWVVY;
   (c)   TLDVMMCTASILNLCAISID;
   (d)   RVTVMISIVWVLSFTISCPL;
   (e)   PAFVVYSSIVSFYVPFIVTL;
   (f)   LAIVLGVFIICWLPFFITHI;
   (g)   LYSAFTWLGYVNSAVNPIIY; and
   (h)   TWLGYVNSA.

16. The antagonist of claim 12 wherein the integral
membrane protein is a β1-adrenergic receptor and the
antagonist is a peptide selected from the group
consisting of
   (a)   GMGLLMALIVLLIVAGNVLVIVAI;
   (b)   IMSLASADLVMGLLVVPFGATIVV
   (c)   ELWTSVDVLCVTASIETLCFIALD
   (d)   RGLVCTVWAISALVSFLPILMHWW
   (e)   RAYAIASSVVSFYVPLCIMAFVYL
   (f)   LGIIMGVFTLCWLPFFLANVVKAF
   (g)   RLFVFFNWLGYANSAFNPIIYCRS; and
   (h)   an effective analogue or fragment of (a) to
         (g).

17. The antagonist of claim 12 wherein the receptor is a
β1-adrenergic receptor and the antagonist is the peptide
FFNWLGYANSAFNP or GYANSAFNP.

18.   The antagonist of claim 12 wherein the receptor is
an α1A-adrenergic receptor and the antagonist is a
peptide selected from the group consisting of

      (a)   GVGVGFLAAFILMAVAGNLLVILSV;

      (b)   FIVNLAVADLLLSATVLPFSATMEVL;

      (c)   DVWAAVDVLCCTASILSLCTISV;

      (d)   AAILALLWVVALVVSVGPLLGWKEP;

      (e)   AGYAVFSSVCSFYLPMAVIVVMYC;

      (f)   LAIVVGVFVLCWFPFFFVLPLGSL;

      (g)   EGVFKVIFWLGYFNSCVNPLIYPCS; and

      (h)   an effective analogue or fragment of (a) to
           (g).

19.   The antagonist of claim 12 wherein the receptor is
an α1A-adrenergic receptor and the antagonist is the
peptide VFKVIFWLGYFNSCVN or VFKVIFWLGYFNS.

20.   The antagonist of claim 12 wherein the receptor is a
vasopressin type 2 receptor and the antagonist is a
peptide selected from the group consisting of

      (a)   AELALLSIVFVAVALSNGLVLAALA;

      (b)   IGHLCLADLAVALFQVLPQLAW;

      (c)   AVKYLQMVGMYASSYMILAMTL;

      (d)   VLVAWAFSLLLSLPQLFIFAQ;

      (e)   TYVTWIALMVFVAPTLGIA;

      (f)   MTLVIVVVYVLCWAPFFLVQLW; and

      (g)   LLMLLASLNSCTNPWIYASF.

21.   The antagonist of claim 12 wherein the receptor is
vasopressin type 2 receptor and the antagonist is the
peptide LMLLASLNSCTNPWIY.

22.   The antagonist of claim 12 wherein the integral
membrane protein is a CCR5 receptor and the antagonist is

a peptide selected from the group consisting of

  (a) LLPPLYSLVFIFGFVGNMLVILILINC;

  (b) LLNLAISDLFFLLTVPFWAHY;

  (c) LLTGLYFIGFFSGIFFIILLTI;

  (d) VTFGVVTSVITWVVAVFASLPGIIF;

  (e) VILGLVLPLLVMVICYSGIL;

  (f) LIFTIMIVYFLFWAPYNIVLLLNTF;

  (g) AMQVTETLGMTHCCINPIIYAFVG; and

  (h) an effective analogue or fragment of (a) to (g).

23. The antagonist of claim 12 wherein the receptor is
CCR5 receptor and the antagonist is the peptide
LYSLVFIFGFVGN or MQVTETLGMT.

24. The antagonist of claim 11 wherein the integral
membrane protein is a tyrosine kinase receptor selected
from the group consisting of

  (a) an epidermal growth factor receptor;

  (b) a fibroblast growth factor receptor;

  (c) a vascular endothelial growth factor receptor;
       and

  (d) a tyrosine kinase A receptor.

25. The antagonist of claim 11 wherein the integral
membrane protein is epidermal growth factor receptor erb3
and the antagonist is the peptide MALTVIAGLVVIFMMLGGTFL
or LTVIAGLVVIF.

26. The antagonist of claim 6 wherein the integral
membrane protein is a bacterial energy-dependent
transporter.

27. The antagonist of claim 26 wherein the transporter
is the E.coli F_1F_0 ATPase and the antagonist is a peptide

selected from the group consisting of

    (a)   MAAAVMMGLAAIGAAIGIGILGG;

    (b)   LAAIGAAIGIGIL;

    (c)   NATILGQAIAFVLFVLFCM;

    (d)   GQAIAFVLFVL; and

    (e)   an effective analogue or fragment of (a) to (d).

28.   The antagonist of claim 8 wherein the integral membrane protein is a mammalian energy-dependent transporter.

29.   The antagonist of claim 8 wherein the integral membrane protein is a transporter protein.

30.   The antagonist of claim 29 wherein the integral membrane protein is a dopamine transporter protein and the antagonist is a peptide selected from the group consisting of

    (a)   FLLSVIGFAVDLANVWRFPYL;

    (b)   GAFLVPYLLMVIAGMPLFYM;

    (c)   GVGFTVILISLYVGFFYNVII;

    (d)   WQLTACLVLVIVLLYFSLW;

    (e)   VVWITZTMPYVVLTALLL;

    (f)   VCFSLGVGFGVLIAFSSY;

    (g)   IVTTSINSLTSFSSGFVVFSFL;

    (h)   LPLSSAWAVVFFIMLLTGLI;

    (i)   LFTLFIVLATFLLSLFCVT;

    (j)   GTSILFGVLIEAIGVAWFYGV;

    (k)   LCWKLVSPCFLLFVVVVSIV;

    (l)   LGWVIATSSMAMVPIYAAY; and

    (m)   an effective analogue or fragment of (a) to (l).

31.   The antagonist of claim 29 wherein the integral membrane protein is a dopamine transporter and the

antagonist is the peptide ALGWIIATS or PDWANALGWVIIATS.

32. The antagonist of claim 8 wherein the integral membrane protein is an immune receptor selected from the group consisting of

     (a)   an immunoglobulin receptor;

     (b)   a tumour necrosis factor receptor;

     (c)   a c type lectin;

     (d)   a cytokine receptor;

     (e)   an EGF TMY receptor;

     (f)   a TMR receptor; and

     (g)   an effective analogue or fragment of (a) to (f).

33. The antagonist of claim 32 wherein the immune receptor is a CD4 receptor and the antagonist is the peptide LIVLGGVAGLLLF or MALIVLGGVAGILLFIGLGIFF.

34. The antagonist of claim 8 wherein the integral membrane protein is an antigen receptor.

35. The antagonist of claim 34 wherein the receptor is a human T cell antigen receptor and the antagonist is the peptide DTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS or an effective analogue or fragment thereof.

36. A method of inhibiting the function of a prokaryotic or eukaryotic integral membrane protein having at least one transmembrane domain, said method comprising contacting an integral membrane protein with a peptide comprising the amino acid sequence of said at least one transmembrane domain or an effective fragment or analogue of said peptide.

37.   The method of claim 36 wherein the integral membrane protein is a prokaryotic or eukaryotic plasma membrane protein.

38. The method of claim 36 wherein the integral membrane protein is a prokaryotic or eukaryotic intracellular membrane.

39.   The method of claim 37 wherein the integral membrane protein is a mammalian plasma membrane protein.

40.   The method of claim 39 wherein the integral membrane protein is contacted with the antagonist of any of claims 1 to 35.

41.   A method of preventing or treating a disorder in a mammal characterised by disordered function of an integral membrane protein having at least one transmembrane domain, said method comprising administering to the mammal an effective amount of a peptide comprising the amino acid sequence of said at least one transmembrane domain or an effective fragment or analogue of said peptide.

42.   The method of claim 41 wherein the integral membrane protein is a prokaryotic or eukaryotic plasma membrane protein.

43.   The method of claim 41 wherein the integral membrane protein is a prokaryotic or eukaryotic intracellular membrane.

44.   The method of claim 42 wherein the integral membrane protein is a mammalian plasma membrane protein.

100

45. The method of claim 44 wherein the peptide administered to the mammal is the antagonist of any of claims 1 to 35.

46. A method of preventing or treating a disorder in a mammal characterised by disordered function of an integral membrane protein having at least one transmembrane domain, said method comprising inserting into cells of the mammal, *in vivo* or *ex vivo*, a nucleotide sequence encoding the antagonist of any of claims 1 to 35.

47. The method of claim 46 wherein the nucleotide sequence is operably coupled to a promoter which will direct expression of the nucleotide sequence in selected target cells of the subject.

48. A transgenic animal wherein a genome of said animal, or of an ancestor thereof, has been modified by at least one recombinant construct and wherein said recombinant construct has introduced a modification selected from the group consisting of insertion of a nucleotide sequence encoding the antagonist of any of claims 1 to 35.

49. A pharmaceutical composition for treatment of hypertension comprising the antagonist of claim 18 or 19 and a pharmaceutically acceptable carrier.

50. A pharmaceutical composition for the treatment of schizophrenia, psychotic disorders, Huntington's Disease and Tourette's syndrome comprising the antagonist of any of claims 14 to 15 and a pharmaceutically acceptable carrier.

51.   A pharmaceutical composition for treatment of drug
abuse comprising the antagonist of claim 13 and a
pharmaceutically acceptable carrier.

52.   A pharmaceutical composition for treatment of
hypertension, post-myocardial infarction and
tachyarrthymias comprising the antagonist of any of
claims 16 to 17 and a pharmaceutically acceptable
carrier.

53.   A diuretic pharmaceutical composition comprising the
antagonist of claims 20 or 21 and a pharmaceutically
acceptable carrier.

54.   A pharmaceutical composition for treatment of HIV
infection and AIDS comprising the antagonist of any of
claims 22 or 23 and a pharmaceutically acceptable
carrier.

55.   A pharmaceutical composition for control of cell
proliferation in cancer, psoriasis and hyperkeratotic
disorders comprising the antagonist of claim 25 and a
pharmaceutically acceptable carrier.

56.   A pharmaceutical composition for treatment of
substance abuse comprising the antagonist of any of
claims 30 to 31 and a pharmaceutically acceptable
carrier.

57.   An antibacterial composition comprising the
antagonist of any of claims 26 and 27 and a
pharmaceutically acceptable carrier.

58. A method for treating hypertension in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 49.

59. A method for treating schizophrenia, psychotic disorders, Huntington's Disease and Tourette's syndrome comprising administering to the subject an effective amount of the pharmaceutical composition of claim 50.

60. A method of treating drug abuse in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 51.

61. A method of treating hypertension, post-myocardial infarction and tachyarrthymias in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 52.

62. A method of providing diuretic treatment to a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 53.

63. A method of treating HIV infection and AIDS in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 54.

64. A method for controlling cell proliferation in a subject suffering from cancer, psoriasis or a hyperkeratotic disorder comprising administering to the subject an effective amount of the pharmaceutical composition of claim 55.

65. A method of treating substance abuse in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 56.

66. A method of treating a bacterial infection in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 57.

1/23

FIG.1A.

FIG.1B.

VERY LARGE LOOP

DOMAIN

EGF

Extracellular

Transmembrane

Juxtamembrane

R

ATP

S

Tyrosine Kinase

R

Carboxy-terminal tail

FIG.2

FIG.3.

5/23

FIG.4

6/23

FIG.5A

FIG.5B

7/23

FIG.6A

FIG.6B

FIG.7A

FIG.7B

9/23

FIG.8

FIG.9

D2-TM VII 15 min before
(•) Apomorphine

FIG.10A

vehicle 15 min before
(•) Apomorphine

FIG.10B

B-AR-TM- VI 15 min before
(•) Apomorphine

FIG.10C

Rat A D2-TM VII 15 min before
Apomorphine

FIG.11

12 / 23

FIG.12.

FIG.13A

FIG.13B

14/23

FIGURE 14A

FIGURE 14B

FIGURE 14C

FIGURE 14D

15/23

FIGURE 14E

FIGURE 14F

FIGURE 14G

FIGURE 14H

16/23

FIGURE 15A

FIGURE 15B

FIGURE 15C

FIGURE 15D

17/23

FIGURE 15E

FIGURE 15F

FIGURE 15G

18 / 23

FIGURE 15H

FIGURE 15I

FIGURE 15J

FIGURE 15K

19/23

FIG.16

20/23

FIG.17A

FIG.17B

FIG.18

FIG. 19

FIG.20

FIG.21

FIG.22

FIG.23